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ABSTRACT 
 
The very potent antibacterial activity of cecropin B makes it a likely candidate to 
prevent and/or treat Mannheimia haemolytica 1:A infection in the upper respiratory tract 
(URT) of cattle.  The purpose of this study was to ascertain if the URT could be 
transfected with a gene coding for the antimicrobial peptide cecropin B.   By transfecting 
cattle with a gene coding for cecropin B, this study attempted to inhibit colonization of a 
virulent strain of M. haemolytica 1:A in the URT while investigating any possible 
changes in the indigenous and transient nasal flora.     
In this study the antibacterial efficacy of cecropin B for a virulent strain of M. 
haemolytica 1:A was determined.  In vitro results showed that cecropin B was very 
effective in inhibiting this virulent strain of M. haemolytica 1:A within 20 minutes of 
incubation at 37°C.  No inhibition of its activity was observed by incubating cecropin B 
in pooled bovine nasal secretions.  
The nasal passages of calves were aerosolized with different amounts of plasmid 
DNA containing a gene coding for cecropin B.  Results of this study show that calves 
transfected with 50 or 100 µg of plasmid DNA per nostril were able to express cecropin 
B at the mRNA and peptide level.  Detection of the cecropin B gene in control calves 
may indicate the possibility of native bovine cecropin. 
After challenge with a virulent strain of M. haemolytica 1:A, all calves were stressed by 
transportation in a crowded trailer 100 miles for 3 hours.  Seven out of the 8 control 
calves yielded detectible levels of M. haemolytica 1:A in nasal aspirates throughout the 
weeks following challenge.  All 4 calves given 25 µg of plasmid DNA per nostril and two   ix
of the 4 calves given 50 µg of plasmid DNA per nostril yielded detectible levels of M. 
haemolytica 1:A in nasal aspirates following challenge.  However, M. haemolytica 1:A 
was not detected in any calf given 100 µg of plasmid DNA per nostril.  There appeared to 
be no change in the normal bacterial nasal flora.   1
INTRODUCTION 
 
The disease known as pneumonic pasteurellosis was first described in cattle 
during the late 1800’s (Mosier et al., 1989).  Prevalence in the stockyards after shipment 
has earned this disease the common name ‘shipping fever’.  Today ‘shipping fever’ 
continues to be responsible for major economic losses in the North American beef cattle 
industry.  More than a billion dollars are lost annually due to clinical disease and death in 
feedlot cattle (Brennan et al., 1998, Confer et al., 1994).  Pneumonic pasteurellosis is 
multifactorial and complex, with stress and other environmental factors contributing to 
pathogenesis of the disease (Mosier et al., 1989). However, it is believed that a bacterium 
commonly isolated from the nasal passages of healthy cattle is a major cause of 
pasteurellosis (Biberstein et al., 1960).  Mannheimia haemolytica 1:A (formerly 
Pasteurella haemolytica 1:A) produces the fibrinous pneumonia associated with the 
disease
 (Mosier et al., 1989), and is termed the major etiologic agent of bovine 
pneumonic pasteurellosis (Dalgleish, 1990, Frank, 1986).  
While M. haemolytica serotype 1:A is the Gram-negative bacterium generally 
regarded as the cause of bovine pleuropneumonia it can be a normal resident of the 
bovine nasal tract.  Under times of stress, M. haemolytica 1:A proliferates in the upper 
respiratory tract (URT).  Stressors include transportation, crowding, irregular feeding or 
watering, abrupt climate change, and exposure to viral agents or a combination of the 
above (Frank et al., 1986, Yates, 1982).  Stress induced proliferation of  M. haemolytica 
1:A following transportation is most likely the cause of pneumonic pasteurellosis in   2
stockyards (Frank et al., 1986, Yates, 1982).  Treatment within 24 hours of shipment may 
be important for the protection of these cattle. 
Vaccines which provide cattle with consistent immunity to pneumonic 
pasteurellosis are not yet available.  Knowledge of M. haemolytica’s virulence factors 
and the host immune response is necessary for the development of effective vaccines.  
Data obtained from aerosol vaccination of 205 kg calves has shown that aerosol 
vaccination at the level of the middle meatus enhances M. haemolytica 1:A clearance 
from the nasal passage and prevents migration of M. haemolytica 1:A to the lung, while 
vaccination at the level of the tracheal bifurcation does not affect nasal colonization of M. 
haemolytica (Brennan et al., 1998).  Furthermore, vaccination at the level of the middle 
meatus results in the production of IgA type antibodies to various M. haemolytica whole 
cell and outer membrane antigens which can be detected in nasal secretions (Brennan et 
al., 1998).  These studies indicate the importance of stimulating immunity to pneumonic 
pasteurellosis in the URT. 
Since vaccines which provide cattle with consistent immunity to pneumonic 
pasteurellosis are not yet available, most veterinarians rely on antimicrobial agents to 
treat the disease.  Streptomycin, tetracyclines, β-lactam antibiotics, chloramphenicol, 
sulfonamides, and trimethoprim-sulfonamide combinations have all been used to treat 
pneumonic pasteurellosis.  Studies have shown M. haemolytica 1:A to have an increasing 
pattern of resistance to all of these antimicrobial agents (Hartman et al., 1993).   
Public concern for the use of antibiotics in food is once again gaining momentum.  
Although the use of antibiotics may result in significantly harmful residue levels in food 
meant for human consumption, these illegal drug residues are no longer being found in   3
carcasses.  The concern has now shifted to drug-resistant microbes.  Many producers use 
low doses of antibiotics as growth promoters (Ferber, 2003).  The result is an increased 
occurrence of antibiotic resistant bacteria, which may pose a threat to human health 
(Ferber, 2003).  An effort to eliminate the routine use of antibiotics in food animal 
production is underway (Ferber, 2003).  It may be beneficial to find novel antimicrobials 
to prevent and/or treat infection. 
  The Cecropia moth, Hyalophora cecropia, responds to bacterial infection with 
very effective antibacterial activity.  The pupae synthesize several different classes of 
antibacterial proteins (Van Hofsten et al., 1985, Xanthopoulos et al., 1988).  The most 
potent of these are the cecropins, specifically cecropins A, B, C, D, E, and F (Boman et 
al., 1987).  Cecropins are small strongly basic proteins which have a broad spectrum of 
bactericidal activity
 (Steiner et al., 1988), but are unable to disrupt eukaryotic cells 
(Boman et al., 1991).  This clearly implicates their possible usefulness as novel 
antibiotics. Although the exact mechanisms are not fully understood, cecropins have been 
shown to have direct action on bacterial membranes
 (Steiner et al., 1988).  Determining 
the structure of the two cecropin homologues has revealed structural elements common 
among membrane-associated proteins (Steiner et al., 1988).  Primary membrane attack is 
considered to be the cause of both Gram-positive and Gram-negative bacteria lysis 
(Steiner et al., 1988).  Furthermore, binding sufficient amounts of cecropin to form a 
monolayer is necessary to modify the bacterial membranes. 
It is believed that to provide protection against pneumonic pasteurellosis, M.  
haemolytica 1:A should not be allowed to colonize the URT.  The antibacterial activity of 
cecropin B against M. haemolytica 1:A has not been reported previously.  Cecropin B has   4
been shown to possess the broadest bactericidal activity of the cecropin family (Chen et 
al., 1997).  It may be useful for eradication of pathogens from mucosal surfaces because 
it is highly effective against Gram-negative bacteria (Vaara et al., 1994).  Cecropin B not 
only has the ability to effectively inhibit bacterial colonization, but it also neutralizes 
endotoxin.  The very potent broad spectrum antibacterial activity of cecropin B makes it a 
likely candidate to prevent and/or treat infection.  However, cost of production may limit 
this peptide’s practical uses.  The most cost-efficient peptide synthesis methods employed 
at the present time are still unreasonable (Hancock et al., 1998).  One possible cost-
effective approach would be to transfer the cecropin B gene into the species of interest 
and let the recipient’s biosynthesis mechanisms synthesize the peptide.  Although there 
are many indications that a transgenic or gene therapeutic approach may be useful in 
enhancing bacterial resistance in food animals, thereby reducing the use of conventional 
antibiotics, very few studies are available describing transfected mammals expressing 
cecropin B or cecropin B-like peptides.   
 
   5
CHAPTER 1 
 
LITERATURE REVIEW 
 
 
Classification, Economic Impact, and Habitat 
  The Bovine Respiratory Disease (BRD) Complex can be summarized as three 
major entities (Lillie, 1974).  Clinically, these entities are known as enzootic pneumonia 
of calves, atypical interstitial pneumonia, and pneumonic pasteurellosis.  Pneumonic 
pasteurellosis, commonly known as “shipping fever” was first described over a century 
ago (Mosier et al., 1989).  Since then many aspects of the disease have been thoroughly 
investigated.  Despite the extensive amount of research on pneumonic pasteurellosis, its 
continued prevalence in the feedlots is responsible for major economic losses in the 
North American beef cattle industry.  More than a billion dollars are lost annually due to 
clinical disease in feedlot cattle (Brennan et al., 1998, Confer et al., 1994).  Calves 
diagnosed with clinical pneumonic pasteurellosis experience increased weight loss during 
shipment, lower average daily gains, and poorer carcass quality.  The disease is complex 
and multifactorial (Mosier et al., 1989).  However one bacterium is most frequently 
associated with the disease (Biberstein et al., 1960).  The major etiologic agent of bovine 
pneumonic pasteurellosis is Mannheimia haemolytica 1:A (Dalgleish, 1990, Frank, 
1986).  M. haemolytica 1:A (formally known as Pasteurella haemolytica 1:A) is a 
nonmotile, Gram-negative coccobacillus or rod, and a facultative anaerobe.  M. 
haemolytica 1:A expresses many virulence factors which help to facilitate disease.  These 
components include capsular polysaccharide, lipopolysaccharide (LPS) also known as 
endotoxin, and leukotoxin (Conlon et al., 1991, Whiteley et al., 1992).  Other virulence 
factors may include outer membrane proteins (OMPs), a sialoglycoprotease, a   6
neuraminidase and possibly two types of fimbriae (Brennan et al., 1997, Lee et al., 1994, 
Whiteley et al., 1992). 
  M. haemolytica 1:A is considered to be part of the normal bacterial flora in the 
upper respiratory tract (URT) of healthy cattle, and can exist in the nasal cavity in very 
low numbers (Carter et al., 1991, Whiteley et al., 1992).  It is believed that healthy cattle 
can carry undetectable levels of M. haemolytica 1:A for long periods of time (Frank, 
1988).  After shipment or other forms of stress, cattle may shed larger numbers of the 
bacterium (Frank et al., 1986).  Furthermore, M. haemolytica 1:A is likely carried in one 
or more sites distinct from the nasal cavity, specifically the palatine tonsils (Frank et al., 
1992).  The tonsils provide an ideal site for carrying the bacterium due to their location 
(Frank et al., 1992, Lillie et al., 1974).  The use a rifampicin-resistant strain of M. 
haemolytica 1:A allowed researchers to show that the organism colonized the tonsils and 
nasal cavity for more than two weeks in experimentally infected calves and commingled 
calves (Briggs et al., 1998).  Tonsilar localization of M. haemolytica 1:A in healthy cattle 
allows for stress induced colonization of the nasal cavity and shedding of the organism.   
The Normal and Transient Flora of the Bovine Nasal Passage 
  In addition to M. haemolytica, Pasteurella multocida and Haemophilus somnus, 
other bacteria commonly associated with BRD, the nasal passage of cattle is home to a 
diverse collection of bacteria that make up the normal and transient flora.  Although a 
complete listing of all the bacteria found in the nasal passage of cattle does not appear to 
have been reviewed recently, the list of organisms cited in the literature is extensive.  
Some of the more frequently isolated bacteria from the URT include Gram-positive 
bacteria such as Micrococcus, Corynebacterium, Staphylococcus, Streptococcus, and   7
Bacillus as well as Gram-negative bacteria such as Pseudomonas, Actinobacter, 
Moraxella, Neisseria catarrhalis, and Escherichia coli (Corbeil et al., 1985, Woldehiwet 
et al., 1990).  Other members of the bovine nasal flora may include Gram-positive 
bacteria such as Lactobacillus, Streptomyces, and Diplococcus pneumoniae as well as 
Gram-negative bacteria such as Chromobacterium, Achromobacter, Serratia, 
Flavobacterium, Proteus, and Klebsiella (Magwood et al., 1969).  These species of 
bacteria have been found to start colonizing the URT as early as the calf’s first day of life 
(Woldehiwet et al., 1990).  The total bacterial load in the nasal passage increases with 
age, and is influenced by environmental temperature (Woldehiwet et al., 1990).  Studies 
have shown that the population of bacteria in the nasal passage of calves fluctuates 
heavily in types and numbers (Magwood et al., 1969, Woldehiwet et al., 1990).  
Sometimes one genus or species is more dominant than others for random periods of 
time.  As early as 1969 it was shown that M. haemolytica was capable of outnumbering 
the rest of the nasal flora for several days at a time (Magwood et al., 1969). 
  These bacteria, considered normal and transient nasal flora, may enhance or 
inhibit growth of M. haemolytica.  Bacillus isolates were found to inhibit the growth of 
M. haemolytica in vitro (Corbeil et al., 1985).  In contrast, several Gram-positive bacteria 
such as Micrococcus, Corynebacterium, and Staphylococcus were found to efficiently 
enhance the growth of M. haemolytica in vitro (Corbeil et al., 1985).  The two Gram-
negative bacteria Moraxella and Actinobacter enhanced M. haemolytica growth in vitro 
as well (Corbeil et al., 1985).  Corbeil et al. showed that the normal and transient flora of 
the nasal passage can significantly affect the colonization of M. haemolytica 1:A. 
   8
Pathogenesis 
Remaining in the URT of unstressed cattle, M. haemolytica 1:A causes no disease 
in the animal (Lillie, 1974).  Under times of stress in the form of transportation, 
crowding, irregular feeding or watering, abrupt climate change, exposure to viral agents, 
or combination of the above, M. haemolytica 1:A  proliferates in the URT (Frank et al., 
1986, Yates, 1982).   Stress also disrupts M. haemolytica 1:A localization, and allows the 
bacterium to colonize other parts of the respiratory tract.  Conditions such as stress or cell 
damage and inflammation are ideal for M. haemolytica 1:A colonization and proliferation 
in the URT.    Stressed cattle shed large numbers of M. haemolytica 1:A, which can be 
isolated during and immediately after shipment (Frank et al., 1986).  Increased 
colonization and proliferation of M. haemolytica 1:A in the URT allows the organism to 
be inhaled into the lung (Frank, 1988).  Researchers have shown that M. haemolytica 1:A 
can be isolated from droplet nuclei in tracheal air (Whiteley et al., 1992).  In the lower 
respiratory tract (LRT), M. haemolytica 1:A would be easily cleared and no lung damage 
would occur under normal conditions (Shewen et al., 1982).  However, chronic exposure 
to the lung allows M. haemolytica 1:A to overcome clearance mechanisms and to initiate 
pneumonia (Frank, 1988).  Intranasal and intratracheal inoculation of M. haemolytica 
1:A, as well as transthoracic inoculation of M. haemolytica 1:A directly into the lung 
have been shown to produce pneumonic lung lesions (Frank, 1986).   
The respiratory tract immune system operates separately from the systemic 
immune system (McBride et al., 1996, McBride et al., 1999).  In addition, the immune 
response in the upper URT differs significantly from the immune response in the LRT 
(Brennan et al., 1997).  The immune response in the URT is specific, and not associated   9
with damage to the URT.  While the immune response in the URT either prevents or 
controls M. haemolytica 1:A colonization, the immune response elicited by the organism 
in the LRT may cause the damage recognized clinically as fibrinous pleuropneumonia.  
The host immune response in the LRT is highly associated with acute pneumonic 
pasteurellosis (McBride et al., 1999).  Chronic exposure to M. haemolytica 1:A in the 
lung induces inflammation, involving the influx of neutrophils and macrophages, 
extensive fibrin exudation, and enhanced vascular permeability (Whiteley et al., 1992, 
Yates, 1982).  Inflammation and exudate as a result of the host immune response allows 
M. haemolytica 1:A to colonize the induced lesion by hindering clearance and providing 
an excellent iron-rich medium.  M. haemolytica 1:A colonization in the lung and 
immune-mediated damage contribute heavily to the pathogenesis of pneumonic 
pasteurellosis.  Histopathologic examinations of lung lesions reveal M. haemolytica 1:A 
and degrading inflammatory cells surrounding a foci of coagulation necrosis (Whiteley et 
al., 1992, Yates, 1982).  Calves depleted of neutrophils have been shown to be somewhat 
resistant to lung lesion development (McBride et al., 1999).  It is believed that 
neutrophils may be the primary effector of the disease.  Neutrophils can be detected in 
lung lavage fluids within hours after M. haemolytica 1:A inoculation (McBride et al., 
1999). 
Leukotoxin and endotoxin secreted by M. haemolytica 1:A may also elicit an 
inflammatory response (Shewen et al., 1982).  Using a neutrophil mediated pathway, 
leukotoxin damages primary endothelial cells, and kills neutrophils and alveolar 
macrophages (Frank et al., 1986, McBride et al., 1999).  Killing neutrophils in the lung 
contributes to the early formation of lesions (Frank, 1986).  The tissue destruction that   10
can lead to lesion formation is ultimately a result of the release of toxic oxygen radicals 
and proteases from neutrophils (Whiteley et al., 1991).  Endotoxin directly interacts with 
the alveolar and pulmonary intravascular macrophages, causing them to synthesize 
proinflammatory cytokines TNFα, IL1, IL8, procoagulents, proteases and toxic oxygen 
radicals (Whiteley et al., 1991).  It has been shown that endotoxin alone can initiate an 
inflammatory response in the lung (Whiteley et al., 1991).   
One study suggests that immune complex disease (type III hypersensitivity) 
contributes to the development of the host inflammatory response (McBride et al., 1999), 
and that pneumonic pasteurellosis is in part an allergic pneumonitis.  A Type III 
hypersensitivity to M. haemolytica 1:A antigens activates complement resulting in 
inflammation and neutrophilic influx.  However, evidence suggests that M. haemolytica 
1:A colonization in the lung and immune-mediated damage, including a type III 
hypersensitivity both play a role in the pathogenesis of bovine pneumonic pasteurellosis. 
Vaccination Attempts 
  Vaccines which provide cattle with consistent immunity to pneumonic 
pasteurellosis are not yet available.  Bacterins, combined bacterins, live, modified-live, 
viral, and component vaccines have been developed to protect cattle from shipping fever 
(Mosier et al., 1989).  Most elicit some protection; however none of the bacterial 
immunogens have been able to consistently protect cattle in the field.  M. haemolytica 
1:A bacterins have been shown to be ineffective (Frank, 1986) and sometimes harmful.  
One belief is that the bacterins do not elicit antibody responses to the antigens important 
to pathogenesis (Frank, 1986).  Researchers found that serum antibody titers correlated 
directly with resistance to lung challenge (Confer et al., 1983); however another   11
explanation for the failure of bacterins in the field is that they produce an IgG response 
(Frank, 1986, Mosier et al., 1989).  Neutrophils phagocytize M. haemolytica 1:A 
opsonized by IgG, and in turn the neutrophils are killed by leukotoxin released by M. 
haemolytica 1:A (Frank, 1986).  The result is immune-mediated lesion development.   
Since viral infections were associated with M. haemolytica 1:A colonization in the 
lung, many viral vaccines have been developed (Mosier et al., 1989).  Although 
vaccination of cattle against Parainfluenza 3 (PI3) and Infectious Bovine Rhinotracheitis 
virus (IBRV) provided resistance to pneumonic pasteurellosis caused by M. haemolytica 
1:A challenge under laboratory conditions (Frank, 1986), field trials of the vaccines were 
unable to provide cattle with protection (Mosier et al., 1989).  Vaccination for Bovine 
Viral Diarrhea Virus (BVDV) was also targeted, however, as with the other viral 
vaccines failure in field experiments was attributed to the wide range of viruses that can 
elicit pneumonic pasteurellosis (Mosier et al., 1989).  In addition cattle vaccinated with 
viral vaccines were still susceptible to M. haemolytica 1:A.  In the next logical step, 
vaccines which combined M. haemolytica 1:A and viral antigens were developed.  As 
with viral vaccines, combination vaccines provided cattle with protection under 
laboratory conditions, but failed in field experiments (Mosier et al., 1989).  They also 
have the potential, like bacterins, to be more harmful.   
Recombinant leukotoxin (rLKT) vaccines also met with little success (Conlon et 
al., 1991).  Inoculating cattle with a rLKT vaccine did enhance the efficacy of another 
vaccine and decrease clinical signs as well as lung lesions; yet an immune response to 
leukotoxin alone did not protect cattle against pneumonic pasteurellosis (Conlon et al., 
1991).  Leukotoxin does play an important role in the pathogenesis of the disease, but   12
pneumonic pasteurellosis is multifactorial and complex.  Other studies have shown that 
vaccination with various surface antigens such as LPS (endotoxin) and purified capsular 
polysaccharide also failed to protect cattle from pneumonic pasteurellosis (Confer et al., 
1994).  
 Live and modified-live vaccines have been shown to be more effective in 
protecting cattle than any other type of vaccine (Mosier et al., 1989).  Studies have shown 
live M. haemolytica 1:A vaccines to enhance resistance to experimental challenge 
(Confer et al., 1985).  Although live and modified-live vaccines have been more effective 
at eliciting an immune response, they are still not consistent in field experiments.  Most 
vaccines developed thus far have been able to produce some immune response.  
However, previously developed vaccines all have failed to provide cattle with consistent 
resistance to M. haemolytica 1:A and pneumonic pasteurellosis in the field. 
Antibiotic Therapy 
  The use of antibiotics to treat pneumonic pasteurellosis has been generally 
successful (Frank, 1986).  Antibiotics are chemical substances of microbial origin.  They 
can either destroy or inhibit the growth of bacteria.  Antibiotics such as tetracyclines and 
sulfonamides have a broad spectrum of activity against a wide range of bacteria, while 
antibiotics such as fluoroquinolones have a narrow spectrum of activity.  Antibiotics have 
four mechanisms of action.  They may inhibit cell wall synthesis, cell wall function, 
nucleic acid synthesis, or protein synthesis.  In the past, antibiotics were purified from 
media filtrates.  Later they were synthesized.  Today new antibiotic drugs are 
biosynthesized from chemical modification of molecules.     13
  Most veterinarians rely on antimicrobial agents to treat pneumonic pasteurellosis.  
Antimicrobial therapy is a very effective method for both the treatment and prevention of 
BRD (Watts et al., 1994).  The veterinarian may select antibiotics for treatment on the 
basis of perceived efficacy, cost, convenience, availability, toxicity, and residue profile 
(Watts et al., 1994).  Veterinary diagnostic labs assist the veterinarian by performing 
susceptibility tests and providing consistent interpretations of the results (Shyrock et al., 
1996).  By monitoring the susceptibility trends of M. haemolytica 1:A, veterinarians can 
select the most effective antibiotics.  With the occurrence of antibiotic resistant strains of 
bacteria,  the appropriate use of antibiotics should include exposing M. haemolytica 1:A 
to sufficient concentrations of the antimicrobial agents for an appropriate duration as to 
minimize the development of resistant strains (Watts et al., 1994). 
  β-lactam antibiotics such as ampicillin, which inhibit bacterial cell wall synthesis 
have been used to treat pneumonic pasteurellosis in the past.  However, ampicillin 
resistant strains of M. haemolytica 1:A have been frequently encountered (Hartman et al., 
1993, Watts et al., 1994).  A relatively new β-lactam antibiotic, ceftiofur, which is a 
cephalosporin with an extended spectrum of activity, was shown to be very effective 
against M. haemolytica 1:A (Watts et al., 1994).  Using a M. haemolytica 1:A challenge 
model researchers were able to show that a single subcutaneous injection of ceftiofur 
crystalline-free acid sterile oil suspension (CCFA-SS, 100 mg ceftiofur equivalents 
(CE)/ml) of 4.4 to 8.8 CE/kg of body weight was very effective at inhibiting colonization 
in the lung (Hibbard et al., 2002).  The formulation was long-acting and more effective 
than tilmicosin, though alternative sites for injection must be found because subcutaneous 
injections in the neck left ceftiofur residues for extended periods of time (Hibbard et al.,   14
2002).  In a four year survey to monitor the emergence of antibiotic resistant strains of M. 
haemolytica 1:A no strains were found to be resistant to ceftiofur (Watts et al., 1994).   
  Antibiotics which inhibit bacterial nucleic acid synthesis such as sulfonamides 
and sulfonamide-trimethoprim combinations have been used to treat pneumonic 
pasteurellosis in the past as well (Watts et al., 1994).  Studies have shown M. haemolytica 
1:A to have an increasing pattern of resistance to these antibiotics (Hartman et al., 1993).  
It has been speculated that resistance to sulfamethazine is so widespread that its 
usefulness in cattle is limited (Watts et al., 1994).  Flouroquinolones including 
ciprofloxacin, norfloxacin, and enrofloxacin are entirely man made antibiotics, which 
have remarkable potency against many aerobic and facultative anaerobic bacteria 
(Prescott et al., 1990).  All three antibiotics were shown to have a minimum inhibitory 
concentration (MIC) of less than or equal to 0.06 µg/ml for 100% of the M. haemolytica 
1:A isolates tested in vitro (Prescott et al., 1990).  Enrofloxacin, which is approved for 
use in cattle, was shown to have a 0.03 µg/ml MIC for 100% of the M. haemolytica 1:A 
isolates tested (Prescott et al., 1990).   
  Streptomycin, tetracyclines, spectinomycin, chloramphenicol, erythromycin, 
florfenicol, and tilmicosin all inhibit bacterial protein synthesis.  Streptomycin, 
tetracyclines, spectinomycin, chloramphenicol and erythromycin resistant strains of M. 
haemolytica 1:A have been frequently encountered ( Hartman et al., 1993, Watts et al., 
1994).  In a four year survey to monitor the emergence of antibiotic resistant strains of M. 
haemolytica 1:A, tetracycline and spectinomycin were shown to have MICs of 32 µg/ml 
and 64 µg/ml respectively to 90% of the isolates tested (Watts et al., 1994).     15
Administering florfenicol to cattle upon arrival at a stockyard was shown to 
decrease the detection of M. haemolytica 1:A in the nasopharynx (Frank et al., 2002).  
Tilmicosin is a relatively new macrolide antibiotic, with mostly anti-Gram-positive 
bacterial activity.  However, this macrolide can inhibit some Gram-negative organisms 
including Mannheimia, Pasteurella, Haemophilus and Actinobacillus bacteria (Shyrock 
et al., 1996).   In vitro studies have shown tilmicosin to have significant antibacterial 
activity against M. haemolytica 1:A (Hartman et al., 1993).  Tilmicosin was shown to 
have an MIC of less than or equal to 2 µg/ml for 96% of the M. haemolytica 1:A isolates 
tested (Hartman et al., 1993).  However, in the four year survey to monitor the emergence 
of antibiotic resistant strains of M. haemolytica 1:A, tilmicosin effectiveness was found to 
vary substantially (Watts et al., 1994).  Due to increased resistance to erythromycin, 
another macrolide, the usefulness of tilmicosin in the treatment of and protection from 
pneumonic pasteurellosis may decrease (Watts et al., 1994). 
  Public concern for the use of antibiotics in food animals is once again gaining 
momentum.  Although the use of antibiotics may result in significantly harmful residue 
levels in food meant for human consumption, these illegal drug residues are no longer 
being found in carcasses.  The U.S. Department of Agriculture’s (USDA) Food Safety 
and Inspection Service (FSIS) ensure that antibiotic residues in food products are within 
established limits.  The concern has now shifted to drug-resistant microbes.  Many 
producers use low doses of antibiotics as growth promoters (Ferber, 2003).  The result is 
an increased occurrence of antibiotic resistant bacteria, which may pose a threat to human 
health (Ferber, 2003).  An effort to eliminate the routine use of antibiotics in food animal 
production is underway (Ferber, 2003).  In 1996, the U.S Food and Drug Administration   16
(FDA), U.S. Centers for Disease Control and Prevention (CDC), and USDA began 
coordinating under the National Antimicrobial Resistance Monitoring System’s 
(NARMS) Enteric Bacteria program in an effort to provide objective information and 
analysis about trends of antibiotic resistance in animal bacteria due to agricultural 
practices. 
Preventing Colonization of the Nasal Passage 
  The immune response in the URT differs significantly from the immune response 
in the LRT (Brennan et al., 1997).  While the immune response in the URT either 
prevents or controls M. haemolytica 1:A colonization, the immune response elicited in 
the LRT may cause damage.  The immunoglobulin A (IgA) comprises 90% of the 
antibody present in the URT (McBride et al., 1996).  This is much greater than in the 
LRT.  In one study, IgA was not detected at all in lung lavage fluids of cattle receiving 
intrapulmonary inoculations of M. haemolytica 1:A (McBride et al., 1999).  Although 
IgA is present in the LRT, IgG1 is the most dominant antibody in the lung (Brennan et al., 
1997).  Both IgG1 and IgA have been associated with enhanced M. haemolytica 1:A 
clearance in the lung (McBride et al., 1996).  However both immunoglobulins have also 
been implicated in contributing to the inflammatory response leading to acute lung 
lesions (Frank, 1986, Johnson et al., 1986).   
  In the nasopharynx, IgA and a portion of the IgG1 are locally produced (Duncan 
et al., 1972).  By reducing the ability of bacteria to invade mucosal surfaces, IgA is 
believed to be the first line of defense against M. haemolytica 1:A colonization in the 
URT (Roth, 1991).  Since critical numbers of M. haemolytica 1:A must be aspirated into 
the lung to cause pneumonic pasteurellosis (Frank, 1988), reducing the levels of M.   17
haemolytica 1:A colonization in the nasopharynx would provide cattle with protection 
against the disease.  If IgA antibodies could reduce M. haemolytica 1:A colonization in 
the nasopharynx, then finding ways to induce a secretory IgA response on the mucosal 
surfaces in the nasal cavity are paramount.  When attempting to induce mucosal 
immunity, the route of vaccine administration is important (Roth, 1991).  Administering 
the vaccine intranasally is beneficial when trying to induce a secretory IgA response.  
Studies have shown that intranasal vaccination can play a key role in inducing an immune 
response to M. haemolytica 1:A in the nasopharynx (Brennan et al., 1998).  Aerosol 
vaccination at the level of the middle meatus in the nasal cavity of cattle was shown to 
enhance M. haemolytica 1:A clearance from the nasopharynx and prevented migration of 
M. haemolytica 1:A into the lung (Brennan et al., 1998).  Immunoglobulin A antibodies 
were detected in the nasal secretions of these cattle.  This evidence supports a previous 
study in which researchers trying to colonize the nasal passages of cattle found that after 
rapid clearance of M. haemolytica 1:A, the calves responded with antibody titers 
detectable in nasal secretions (Frank, 1988).  However the use of currently available 
vaccines does not allow enough time for an effective immune response to develop before 
the onset of pneumonic pasteurellosis in calves at the feedlots (Frank et al., 2002). 
  It appears there have been very few studies aimed at the use of antibiotics to 
eliminate colonization of the nasal passage.  The use of an effective antibiotic to inhibit 
the rapid colonization of M. haemolytica 1:A in the nasopharynx should reduce the 
occurrence of pneumonic pasteurellosis in cattle arriving at the feedlots.  The use of 
oxytetracycline or the feeding chlortetracycline at the feedlots did not reduce or eliminate 
the colonization of M. haemolytica 1:A in the nasopharynx (Frank et al., 2000b).  In   18
calves experimentally infected with M. haemolytica 1:A, tilmicosin was effective in 
alleviating clinical signs and pathology findings of pneumonic pasteurellosis as well as 
the presence of viable organisms in the lung (Morck et al., 1997).  Furthermore, a single 
subcutaneous injection of 10mg per kg body weight protected the lung for up to 72 hours 
with concentrations well above the MIC for M. haemolytica 1:A (Morck et al., 1997).  
Researchers have also shown that a single dose of 10 mg per kg body weight of 
tilmicosin was more effective at reducing mortality due to pneumonic pasteurellosis than 
ceftiofur, oxytetracycline, or trimethoprim-sulfadoxine (Shyrock et al., 1996).  In a study 
focused on decreasing M. haemolytica 1:A colonization in the nasopharynx, both 
florfenicol and tilmicosin were shown to be effective (Frank et al., 2000a, Frank et al., 
2002).  Florfenicol inhibited M. haemolytica 1:A colonization in the nasal passage for up 
to 4 days, while tilmicosin inhibited M. haemolytica 1:A colonization in the nasal passage 
for up to 6 days (Frank et al., 2002).  There appears to be no advantage to using 
tilmicosin before or after arrival at the stockyard (Frank et al., 2000b).  Using an 
antibiotic such as tilmicosin before or after transport can reduce the occurrence of 
pneumonic pasteurellosis at the stockyards, and would also allow vaccines given before 
transport time to elicit an immune response (Frank et al., 2000b).   
Clinical pneumonic pasteurellosis seems inevitable only after M. haemolytica 1:A 
colonization and proliferation occurs in the URT.  Preventing M. haemolytica 1:A from 
ever colonizing the nasopharynx of cattle would certainly be ideal, although unrealistic.  
Simply controlling the prolific growth of M. haemolytica 1:A by antimicrobial treatment 
or by eliciting an antibody response in the nasal passage would reduce the number of   19
organisms reaching the lungs.  Reduced numbers of bacteria in the LRT would be easily 
cleared with no lung damage, thereby preventing pneumonia before it is started.   
Insect Immunity 
  Insects, like vertebrates, respond to infection with a highly effective immune 
system, both cellular and humoral (Boman et al., 1991).  Although lymphocytes have 
never been found in insects, and they were once thought not to possess any form of 
immunoglobulins, these invertebrates still have a specialized immune system (Boman et 
al., 1987).  However, insect immunity still lacks the high degree of specificity found in 
the immune systems of vertebrates (Boman et al., 1987).  An injury is often the cause of 
infections, for this reason insects will often respond to an injury and other forms of 
infection in a similar manner (Boman et al., 1991).   
  In regards to cellular immunity, different hemolymph cell types have important 
roles in protecting insects.  Generally, six cell types are recognized (Boman et al., 1987).  
They include prohemocytes, plasmatocytes, granulocytes, coagulocytes, spherulocytes 
and oenocytes.  Plasmatocytes and granulocytes, which are granular cells, phagocytize 
smaller bacteria and unicellular fungi (Boman et al., 1987).  Many of the hemocytes work 
in cooperation to encapsulate large aggregates of invading cells or parasites such as 
nematodes (Boman et al., 1987).  Insects respond to large numbers of invading cells by 
the formation of nodules (Boman et al., 1987).  In addition to being involved in 
phagocytosis, plasmatocytes are also involved in capsule and nodule formation (Boman 
et al., 1987). 
  Insects respond to an injection of live bacteria by rapidly removing them from the 
hemolymph with phagocytosis and nodule formation (Boman et al., 1987).  The rapid   20
clearance of bacteria is followed by a short period of RNA synthesis and then subsequent 
protein synthesis (Boman et al., 1991).  The insect is then considered to be immunized 
due to the increased circulation and activity of antibacterial agents in the hemolymph 
(Boman et al., 1987).  In all, approximately 15 to 20 immune proteins are synthesized in 
the humoral immune response.  In diapausing pupae of the saturniid Hyalophora 
cecropia, also known as the giant silk moth, this increase in antibacterial activity is 
mainly due to the synthesis of three novel classes of antibacterial proteins, specifically 
lysozyme, attacins and cecropins (Boman et al., 1991).  These immune factors were first 
purified in 1980, and were first discovered in H. cecropia. 
  Lysozyme was the first antibacterial protein purified from insects (Boman et al., 
1987).  Since its initial discovery, lysozyme has been found in many other insects 
(Boman et al., 1991).  Lysozyme is an enzyme, therefore it has catalytic activity.  It was 
found to contain 120 amino acid residues, a substrate binding groove and four disulfide 
bonds (Boman et al., 1987).  Lysozyme can be isolated from the larvae of nonimmunized 
H. cecropia, but not in the pupae.  However, lysozyme can be induced in both by the 
injection of nonpathogenic bacteria (Boman et al., 1987).  It is not the main antibacterial 
protein responsible for immunity in insects because insects can still eliminate many 
lysozyme-resistant bacteria (Boman et al., 1991).  It is believed that lysozyme works in 
concert with attacins and cecropins in H. cecropia, and probably in concert with the main 
antibacterial proteins in other insects.  Lysozyme has been shown to have limited 
antibacterial activity.  It is only bactericidal to a few Gram-negative bacteria such as 
Bacillus megaterium, B. subtilis, and Micrococcus luteus (Boman et al., 1991).  
Cecropins A and B have also been shown to kill B. megaterium and M. luteus (Boman et   21
al., 1991).   B. subtilis is the only organism shown to be sensitive to lysozyme but 
resistant to cecropins. The main function of lysozyme may not be bactericidal, but to 
clear the murein sacculus or peptiglycan and cell wall material left after the action of 
attacins and cecropins (Boman et al., 1987). 
  Attacins were first isolated from the immune hemolymph of H. cecropia pupae 
injected with live bacteria (Boman et al., 1987).  Six different attacins were isolated and 
found to contain 183 to 188 amino acid residues (Boman et al., 1991).  Furthermore, it 
was found that attacins existed in two forms, basic and acidic peptides.  It is believed that 
attacins work in concert by facilitating the action of lysozyme and cecropins (Boman et 
al., 1991).  It was shown that attacins only act on growing bacteria, and that their 
antibacterial activity is limited to a small number of bacterial species (Boman et al., 
1991).  In larvae of the Chinese Oak Silk Moth, Antheraea pernyi, attacin was found to 
inhibit Escherichia coli and two other bacteria in the gut (Boman et al., 1987).  It was 
shown that the bactericidal action of attacins is directed to the outer membrane (Boman et 
al., 1991).   
  Of the three families of antibacterial proteins in H. cecropia, the cecropins have 
the most potent bactericidal activity (Boman et al., 1987, Chen et al., 1997).  The 
cecropins were discovered in 1980 when Hans Boman and his research group 
successfully separated them biochemically and functionally from lysozyme in H. 
cecropia (Boman et al., 1991).  Cecropins A and B were isolated initially (Boman et al., 
1987), since then this family has been extended to include cecropins C, D, E, and F (Chen 
et al., 1997, Hultmark et al., 1982).  The cecropins have highly homologous sequences 
consisting of 35 to 39 amino acid residues.  Cecropins in general have a broad spectrum   22
of antibacterial activity against several Gram-positive and Gram-negative bacteria 
(Boman, 2003).  There appears to be little known about the minor cecropins C, E, and F; 
cecropins A and B have been shown to be highly active against both Gram-positive and 
Gram-negative bacteria, while cecropin D has shown high activity only against E. coli 
and Acinetobacter calcoaceticus (Boman et al., 1991).  Cecropin B is slightly more 
potent than cecropin A.  Furthermore, cecropins have been shown to lyse bacteria, while 
leaving eukaryotic cells intact; unless they have been transformed (Boman et al., 1991, 
Moore et al., 1995).  Since they were originally found in H. cecropia, cecropins have 
been found in other lepidopterans (butterflies and moths), dipterans (flies, etc.), other 
insect orders, pigs, and a marine protochordate (Hancock et al., 1998). 
  It was once thought that all invertebrates including insects did not possess any 
form of immunoglobulins.  Hemolin was the first immunoglobulin-like molecule thought 
to be part of the immune response, isolated from an invertebrate (Boman et al., 1991).  
Like lysozyme, attacins, and cecropins, hemolin was first characterized from the 
hemolymph of H. cecropia (Boman et al., 1991).  Although little is known about 
hemolin, it is the most abundant immune protein in H. cecropia.  It has no antibacterial 
activity, but has been shown to bind bacteria in vitro (Boman et al., 1991).  Once bound, 
hemolin complexes with another hemolymph protein.  This complex is then bound by 
hemocytes, causing it to disaggregate.  Studies indicate that hemolin is involved in 
self/nonself recognition (Boman et al., 1991).  Hemolin is produced as part of an immune 
response, but can preexist in hemolymph and the fat body (Boman et al., 1991). 
  Insect orders other than lepidoptera produce lysozyme, attacin-like, and cecropin-
like peptides as well as unique antibacterial peptides of their own.  The fly, Phormia   23
terranovae, produces diptericin in response to infection (Boman et al., 1991).  Honeybees 
produce apidaecins and abaecin (Boman et al., 1991).  The main component of bee 
venom, melittin, which has some bactericidal activity, has been shown to be similar in 
structure to cecropin (Boman et al., 1991).   
The Cecropin Gene 
  The cecropin locus in H. cecropia is about 20 kb long (Boman et al., 1991).  The 
transcriptional region of cecropin B was the first to be sequenced from H. cecropia 
(GenBank Accession No. X07404) (Boman, 2003, Xanthopoulos, et al., 1988).  The 
sequence was shown to include a 0.79 kb Bg/II fragment and an adjacent 0.53 kb Bg/II-
Pvu I fragment (Xanthopoulos et al., 1988).  The gene is a typical eukaryotic gene.  A 
consensus sequence, known as the TATA box, is found in the promoter region of most 
genes transcribed by eukaryotic RNA polymerase II.  The consensus sequence is 
generally 5’-TATAAAA-3’, and is important in determining the accurate position at 
which transcription is initiated.  The cecropin B gene contains a 5’-TATAAA-3’ 
sequence at position –30 in the 5’ flanking region, which is homologous to the TATA 
box consensus (Fig. 1.1) (Boman, 2003, Xanthopoulos et al., 1988).  Most eukaryotic 
genes also have another consensus sequence in the promoter located upstream of the start 
of transcription.  This sequence, 5’-GG T/C AATCT-3’, is a requirement for transcription 
to proceed smoothly.  In the gene coding for cecropin B the CAT box is present as the 
sequence 5’-CAAAT-3’ found at position –68 (Fig. 1.1) (Boman, 2003, Xanthopoulos et 
al., 1988).  Also a polyadenylation signal represented by the sequence 5’-AATAAA-3’ or 
5’-ATTAAA-3’ is required for the transcription of eukaryotic genes.  The cecropin B 
gene was shown to have two such signals of the sequence 5’-AATAAA-3’, located in the    24
1 aga tct att gga act gat ata aacacc att aat aca cat taa gat att aaa ttt tat ggt ttt gtt ccgaacaga att
79 aac aat tta aat tcg aataaaaaa tat tac cgt tgt aaaata ctc gtg att tta cga cat gtg tta ata tta aaa ttg
157 gaa gct ctc gtt taa aca att ttg aaa tat ttt tct gtg gtg tcc aaggag ggt tta ataaaaaag ttc caa act ctt
235 tgaaaaagt aac tac cat aat aat gta gta gat aca tat gta gta aat att ata cgt ata aat gtg ccg ttg gac ata
313 att tac aat taaaaaaaa t t ac g t c g at t tc a tt t ga a tt t tg a cccc ggt cag ctt cct ttt acg ttg cgaggg aat
391 tta cat tta tct acg ctg taa cat ccaaac tgt tta cat ttg acccca aataagcgg tta tcagac ttg act ccg ctg
  CAT Box TATA Box
469 cat aag tgc taa ttt aataaa ctc ttg caaatg tct gcg tca ttt att gtagcaaag att tta ata taaaacaga caa
5' cap mRNA start
547 tta att tat tcg ata cat cat tcat c tc g tg a c ttc ttc gtg tgt ggt gtt tac cta tat atc taa att taa tat ttc
start
metasnpheser arg ile phephephe valphe ala leu val leu ala
MNFSR IFFFV F A L V L A
625 gtt tat taa aat tta ata tat ttc gac g atg aat ttc tcaaggata ttt ttc ttc gtg ttc gct ttg gtt ctg gct
leu ser thr val ser ala ala pro glu pro lys trp lys val phe lys lys ile
LSTV S A A PEPKW K V FKKI
701 ttg tcaaca gtt tcg gct gcgccagagccgaaa tgg aaa gtc ttc aagaaa att gta agt tta ttt tat att tta ctt
779 aat agt gtt tag atc tgt att taa tga tcc att tta aaaagtaca ctt ttg aaa tta agacgacgg att ttt att tct
857 att agccacaaa tac aat cga att tct caa tcgaaa gta ttt ttc gac atc tct gag gta gct tta gct agaaaa aat
935 a t tt a tt t tt a a a a a ata ttt ttt tgt tgc gtt tct gat tta agt atg ttt att tacaaaagt atg tat gccaaa tta
1013 tcc tca att tat ata tca gccaag ttt tca aaa gtc tta gaa agt aaa tat aat att att ctt taa agc tat caa cag
1091 cta tat ttg tac taa ctg ttc ttg gat att ttt tcg ttt gcaaaa tac tct att ttt taa att tgt gtt aat atc ata
1169 ttg tgg tta ctt ttt ttc ata ttc aaaata act tca aagaaaggc taa taa tgg tta act ttt gaaacc gta cct aat
glu lys met gly argasn ile argasn gly ile val lys ala gly pro ala ile
EKMGR NIR NG I V K A GPA I
1247 aaa ttt gtg ttt ttt ttt cca g gaaaaa atg ggt cgcaac atc agaaac ggt att gtc aag gct ggaccggcg atc
ala val leu gly glu ala lys ala leu gly
A V LGEA K A LG s t o p
1323 gcg gtt tta ggcgaagccaaagcg ctagga taa aat aat ttt aat tta aaa tat tat tta ttg ataaac gtt ttt gtt
      polyA signal
1401 act att ata tta ttt aat tta gat aataaa ttt aat tta taa att ttc att gtt aat aat tta att tgt cct tta ata
polyA signal
1479 ata ggt tta ataacagga cat cct tta tac ctt gcg tgc gtt tgaaaataa act tta ttt aat gt
Figure 1.1. The cecropin B gene =exon =intron  
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3’ end of the gene (Fig. 1.1) (Boman, 2003, Xanthopoulos et al., 1988).  The gene also 
contains a conserved, insect specific 5’ cap site sequence, 5’-ATCATTC-3’ (Fig. 1.1) 
(Boman, 2003, Xanthopoulos et al., 1988).   
  Cecropin B is synthesized as a prepro molecule, and there is one transcriptional 
unit for preprocecropin B.  The coding region contains two exons separated by only one 
intron (Fig. 1.1).  The transcriptional unit is 1035 bp long from the cap site to the second 
polyadenylation signal.  The gene contains a 90 bp-long mRNA untranslated region prior 
to the start codon (AUG) (Xanthopoulos et al., 1988).  The signal peptide, the 
prosequence, and the first eight amino acid residues of mature cecropin B peptide are 
translated from the first exon.  A single 514 bp intron separates the first exon from the 
second exon.  The second exon contains the rest of the code for mature cecropin B plus 
one glycine residue (Fig. 1.1) (Xanthopoulos et al., 1988).   
  Xanthopoulos et al. suggested that there may be 3 to 5 copies of the gene for 
cecropin B present in the H. cecropia genome.  Since cecropins A, B, and D show 62% to 
65% homology, they most likely originated from gene duplications.  Furthermore, it has 
been shown that transcripts for cecropin A and B are made simultaneously while there is 
a slight delay for the transcript of cecropin D (Boman et al., 1991). Kinetic activities of 
these three cecropins have shown a similar delay in cecropin D antibacterial activity 
(Boman et al., 1991). 
    Certain hemocytes are only slightly responsible for the synthesis of immune 
proteins in H. cecropia (Boman et al., 1991).  A specialized organ known as the fat body 
is believed to be the main organ responsible for the synthesis of immune proteins in both 
larvae and pupae of H. cecropia.  In vitro studies have shown that fat bodies dissected   26
from immunized H. cecropia pupae could synthesize active immune proteins (Boman et 
al., 1991).  It was further shown that LPS was enough to induce isolated fat bodies to 
produce immune proteins (Boman et al., 1991).   
Cecropin B Structure and Activity 
  The cecropins are strongly basic peptides containing 35 to 39 amino acid residues.  
The NH2-terminal region is strongly cationic, while the COOH-terminal region is a long 
hydrophobic stretch (Boman et al., 1991).  All cecropins have a highly conserved 
tryptophan at position 2, single and double lysines at positions 5, 8, and 9, and arginine at 
position 12 (Fig. 1.2).  Due to these conserved sequences found in several different 
species of insects there must have been strong selection pressure for the cecropin genes 
(Boman et al., 1991). 
Lys(K)-Trp(W)-Lys(K)-Val(V)-Phe(F)-Lys(K)-Lys(K)-Ile(I)-Glu(E)-Lys(K)-Met(M)-Gly(G)-Arg(R)-Asn(N)-Ile(I)-
Arg(R)-Asn(N)-Gly(G)-Ile(I)-Val(V)-Lys(K)-Ala(A)-Gly(G)-Pro(P)-Ala(A)-Ile(I)-Ala(A)-Val(V)-Leu(L)-Gly(G)-Glu(
Ala(A)-Lys(K)-Ala(A)-Leu(L)-NH2
Figure 1.2. Primary structure of cecropin B  
  All cecropins are synthesized as larger prepro molecules with about 62 to 64 
amino acid residues (Boman et al., 1991).  In the NH2-terminus about 24 to 26 of the 
amino acid residues are not present in any mature cecropin protein.  About 22 of them are 
probably part of the signal peptide (Boman et al., 1991).  The amino acid sequence of 
preproceropin B suggests that the primary translation product is processed in two, maybe 
three steps to yield mature cecropin B (Van Hofsten et al., 1985).  Cecropin B is 
translated as a 62 amino acid residue precursor molecule including a leader peptide and a 
COOH-terminal glycine residue (Fig. 1.1).  The leader or signal peptide is 26 amino acid 
residues long on the NH2-terminus.  In vitro studies have shown that the leader peptide   27
could be removed by one or more protolytic enzymes (Van Hofsten et al., 1985).  
Following the activity of membrane-bound signal peptidase, a dipeptidypeptidase could 
recognize the two dipeptide units in Ala-Pro-Glu-Pro (Fig. 1.1) that precede the NH2-
terminus of mature cecropin B (Van Hofsten et al., 1985).  Natural cecropin B was found 
to have an amide group bound to the COOH-terminal leucine residue (Fig. 1.2) (Van 
Hofsten et al., 1985).  It is likely that another step in the processing of preprocecropin B 
involves the donation of nitrogen from the COOH-terminal glycine residue found in the 
precursor molecule (Fig 1.1).  
All the endogenous antimicrobial peptides found in plants and animals have 
common structural motifs.  They are typically cationic, containing excess lysine and 
arginine residues, amphipathic molecules composed of 12 to 45 amino acid residues 
(Hancock et al.,1998).  Some are α-helical structures, especially in anionic solvents or 
mixed with anionic phospholipid membranes.  Others contain β-sheet secondary 
structures stabilized by intramolecular cysteine disulfide bonds. 
The structure of cecropin B as predicted by sequence analysis as well as circular 
dichroism spectroscopy, and determined by Nuclear Magnetic Resonance (NMR) of 
cecropin A is a near-perfect NH2-terminal amphipathic α-helix, and a COOH-terminal 
hydrophobic α-helix joined by a flexible hinge at positions 23 and 24 (Fig. 1.2, Gly and 
Pro) (Chen et al., 1997, Durell et al., 1992, Moore et al., 1995).  The amphipathic α-helix 
contains both a hydrophilic and a hydrophobic (lipophilic) group.  The helix-bend-helix 
structural motif is common among many cationic lytic peptides (Hancock et al., 1998).  
The NH2-terminus of cecropin B is highly basic due to a number of lysine (n=6) and 
arginine (n=2) residues.  An unusually polarized NH2-terminal amphipathic helix is also a   28
very common structural motif of membrane associated proteins (Steiner et al., 1988).  
Due to a lysine residue and amidation on the end, the hydrophobic COOH-terminal α-
helix also has a positive charge.  Cecropin B, as well as all cecropins, is devoid of 
cysteine residues (Moore et al., 1996).   
The lytic activity of cecropin has been widely studied.  Cecropin B can cause 
rapid lysis of bacterial cell membranes (Boman, 2003, Steiner et al., 1998).  There are 
two theories explaining the action of cecropin B.  The most likely mechanism of action 
involves aggregation and insertion of the peptides into the membrane, pore formation, 
and then subsequent membrane disruption (Hancock et al., 1998, Wang et al., 1999).  The 
alternative hypothesis states that the peptides may accumulate on the membrane causing 
cooperative permeabilization (Hancock et al., 1998).  This destabilization of the 
membrane has been dubbed the ‘carpet effect’ and is comparable to the activity of a 
detergent (Wang et al., 1999).  Evidence has shown that the rate of lysis is dependent on 
the concentration of cecropin (Boman et al., 1991).  Binding sufficient amounts of 
cecropin to form a monolayer is necessary to modify the bacterial membranes (Steiner et 
al., 1988).  Bacteria which are resistant to cecropin still bind large amounts in a non-
productive manner.  Eukaryotic cells are resistant because they avoid the binding of 
cecropin B.  The indication is that cecropins act stoichiometrically.  The activity of 
cecropin B is a matter of mass action, and is not catalytic in nature (Steiner et al., 1988). 
In vitro and in vivo studies have shown that cecropins possess both antibacterial 
and anticancer activity (Moore et al., 1995, Moore et al., 1996).  Cecropins are thought to 
induce ion channels in membranes followed by cell lysis.  The rapid membrane 
disruption of bacterial cells induced by cecropin B is most likely caused by primary   29
membrane attack (Steiner et al., 1988).  By assimilating knowledge of cecropin and other 
antibacterial peptides into three dimensional atomic-scale computer models researchers 
predicted that cecropins may assemble in membranes to form two types of ion channels 
(Durell et al., 1992).  Type I ion channels may be formed by a collection of bound dimers 
with the pore formed by the transmembrane COOH-terminal helices (Durell et al., 1992).  
These dimers could then be arranged into a hexagonal lattice.  This could explain the 
large amounts of cecropin that bind to the bacterial membrane (Steiner et al., 1988).  If a 
concerted conformational change of a Type I ion channel in which the pore was formed 
by the NH2-terminal helices would occur, a larger Type II ion channel would be formed 
(Durell et al., 1992).  Cecropins as well as other antimicrobial peptides have been shown 
to form ion channels on artificial membranes such as liposomes (Boman et al., 1991).  
Cecropin B has been shown to lyse negative and neutral liposomes, but not positive ones 
(Steiner et al., 1988, Vaara et al., 1994).  It is believed that negatively charged 
headgroups on the membrane surface attract and bind the positively charged NH2-
terminal helices (Durell et al., 1992).  The hydrophobic COOH-terminal helices are then 
inserted into the membrane core.  The positively charged NH2-terminal helices are 
pushed into the membrane by positive potential on the same side of the membrane as the 
peptides (Durell et al., 1992).  Transmembrane NH2-terminal helices become associated 
with the hydrophilic residues faced inward forming an aqueous pore; the hydrophobic 
residues then are in contact with the aliphatic phase of the membrane.   
Changing the structure of the NH2-terminal α-helix of cecropin B lowers its 
membrane binding affinity (Steiner et al., 1988).  An antibacterial peptide containing two 
amphipathic α-helical segments derived from cecropin B was shown to have a similar   30
ability to lyse bacteria with a 2 to 6 fold higher potency in lysing cancer cells when 
compared to cecropin A (Srisailam et al., 2000).  The researchers summarized that an 
amphipathic α-helix is indeed necessary for performing effective cell killing activity.  
Furthermore, it was recently shown that cecropin B and cecropin B analogues which 
contain at least one amphipathic α-helix lyse cells by the formation of pores (Chen et al., 
2003).  In contrast, B analogues which lack an amphipathic α-helix appear to follow the 
‘carpet effect’ model. 
Lytic peptides, which were designed to have extra cationic residues, were less 
effective in breaking liposomes and killing bacteria but more effective in lysing cancer 
cells (Chen et al., 1997).  It is possible that the content of the α-helix is not the main 
factor of antibacterial and anticancer activity, but that the characteristics of the α-helix 
itself may be important.  When eukaryotic cells are transformed they usually have more 
exposed anionic lipids, and microvilli on the cell membrane tend to make the surface 
more accessible (Chen et al., 1997).  The greater susceptibility to cationic lytic peptides 
of cancer cell membranes may be a possible explanation for the difference between the 
lytic activities on eukaryotic cells versus eukaryotic cancer cells. 
In another study, researchers tested the effect of pH on the ability of cecropin B to 
lyse liposomes of low or high levels of anionic content.  They were able to show that at 
high pH, cecropin B reached maximum lytic activity on both types of liposomes (Wang 
et al., 1999).  Here, the researchers summarized that pH is a major factor in the ability of 
cecropin B to effectively lyse membranes and that secondary structure and binding ability 
may not be the main determinants of lytic peptide activity.   31
Although cecropins have a broad spectrum of activity against both gram-positive 
and Gram-negative bacteria, the latter are generally more susceptible to cecropins 
(Boman, 2003, Moore et al., 1996).  The cytoplasmic membrane is the predicted site of 
the lethal action of cecropin B.  The cytoplasmic membrane of Gram-positive bacteria is 
inherently more resistant to cecropin B (Boman, 2003, Moore et al., 1996).  In Gram-
negative bacteria, cecropin B must be able to cross the outer membrane to access the 
cytoplasmic membrane.  There is evidence to suggest that cecropin B disrupts the 
bacterial outer membrane.  After treatment with cecropin B, electron microscopy can be 
used to show the outer membrane disruption of E. coli (Moore et al., 1996).  If the 
peptide initially binds through electrostatic attraction, this could explain the efficacy of 
cecropin B on the outer membranes of Gram-negative bacteria.  This electrostatic 
attraction may be absent or reduced in the less susceptible Gram-positive bacteria.  
Cecropin B initially interacts with the highly anionic outer membrane glycolipid, LPS, of 
Gram-negative organisms (Hancock et al., 1998).  Then the peptide accesses the 
cytoplasmic membrane by local disruption of the outer membrane.  Consequently, a 
highly anionic outer membrane may not be completely necessary.  One study showed that 
cecropin B was almost as active on wild-type enteric bacteria as it was on their mutant 
strains that have very defective outer membranes (Vaara et al., 1994).  Furthermore, 
mutant strains which had less anionic LPS were completely susceptible to cecropin B 
(Vaara et al., 1994).  Even though the natural L-isomer and the D-enantiomer of cecropin 
B both form α-helical secondary structures (inverse conformation), they differ in their 
interaction with the chiral acidic sites of LPS (Bland et al., 2001).  When compared to L-  32
cecropin B however, the difference in LPS interaction does not affect D-cecropin B 
antibacterial activity against Gram-negative bacteria. 
In summary, cecropin B is not only one of the most potent broad spectrum lytic 
peptides, but it is also very effective against Gram-negative organisms.  It can cause 
rapid, even instantaneous lysis, of bacteria cells by disrupting the cytoplasmic membrane.  
The strong cationic amphipathic α-helix is required for effective binding to the bacterial 
membrane, but does not function through chiral-specific receptors.  Primary membrane 
attack through the formation of ion channels is the most likely cause of cell lysis.  
However, the density of bound cecropin B must be high for such pores to form.  
Cecropins in the Animal Kingdom  
  Cecropin homologues have been isolated from Antheraea pupae, the flesh-fly 
Sarcophaga, the silkworm Bombyx, the tobacco hornworm Manduca, Drosophila, the 
blood cells of a marine protochordate, and even porcine intestines (Boman et al., 1991, 
Hancock et al., 1998, Marshall and Arenas, 2003).  These findings suggest that cecropins 
may be widespread throughout the animal kingdom.  In every species they contribute to 
the animal’s innate immunity.   
 Cecropin  P1 was discovered when researchers isolated anti-E. coli factor from the 
upper part of the porcine small intestine (Lee et al., 1989).  Sequence analysis determined 
this factor to be a 31 amino acid residue, cysteine-free, cecropin-like peptide.  The 
secondary structure is not the helix-bend-helix motif found in cecropin B, but a single 
long α-helical structure (Srisailam et al., 2000).  The NH2-terminus begins with an 
amphipathic structure of 4 to 5 turns followed by a shorter hydrophobic region of 1 to 2 
turns.  Also, the carboxyl group on the COOH-terminus of natural cecropin P1 is not   33
amidated (Lee et al., 1989).  It has been shown that cecropin P1 kills bacteria by 
instantaneous lysis, and more peptide is required to kill more bacteria (Boman et al., 
1993).   
Other Antimicrobial Peptides  
  Cecropins were first isolated from insects, then subsequently from mammals 
(Boman et al., 1987).  This contradicted the belief that the use of antimicrobial peptides, 
especially cecropins, was limited to the insect immune response.  Soon after defensins 
were first discovered in mammals, they were subsequently found in insects (Lee et al., 
1989).  These findings suggested that not only cecropins, but all antimicrobial peptides 
are widely distributed in the animal kingdom.  This distribution is most likely due to the 
fact that RNA and protein synthesis of antimicrobial peptides is much faster and easier 
than facilitation of the mechanisms dependent also on cell proliferation (Lee et al., 1989).  
Hence antimicrobial peptides provide fast and easy defense.  In addition to diptericin 
from flies and apidaecins and abaecin from honeybees, researchers have found lytic 
peptides in other insects, bacteria, crustaceans, amphibians, and mammals. (Boman et al., 
1991, Hancock et al., 1998, Marshall and Arenas, 2003, Moore et al., 1996).   These 
peptides include defensins, magainins, bactenecins, lactoferricins, and cathelicidins as 
well as tachyplesin, protegrin, indolicidin, and nisin.  The innate immunity of most 
animals relies heavily on the protection provided by antimicrobial peptides. 
  To protect their skin against microorganisms, frogs produce the antimicrobial 
peptides known as magainins (Boman et al., 1991).  Magainins were first isolated from 
the skin of the African clawed frog, Xenopus laevis (Hancock et al., 1998).  Magainins 
are 23 amino acid residues long, lysine-rich, cysteine-free, and are believed to form α-  34
helical secondary structures.  They are synthesized in the granular gland which stores 
large amounts of active peptides.  Magainins are active against many Gram-positive and 
Gram-negative bacteria.  They have been shown to form pores in the cell membrane, but 
are relatively nontoxic to untransformed eukaryotic cells (Hancock et al., 1998). 
  Defensins were first discovered in mammals then subsequently in insects (Lee et 
al., 1989).  Cecropins and defensins are very different types of molecules.  Defensins are 
cysteine-rich and form β-sheet secondary structures as opposed to cysteine-free α-helical 
secondary structures (Hancock et al., 1998).  Due to unique consensus sequences and 
placement of disulfide bonds they have been divided into two families, classical and β-
defensins (Selsted et al., 1996).  All defensins are similar in that they have identical folds 
and six cysteine residues which form three intramolecular disulfide bonds (Hancock et 
al., 1998).  Defensins have been shown to form ion channels on artificial membranes 
(Boman et al., 1991).   
  β-defensins are highly cationic and contain 38 to 42 amino acid residues.  They 
can be found in most species including humans, birds, rats, mice, Guinea pigs, rabbits, 
cattle, and sheep (Diamond et al., 2000, Huttner et al., 1998b, Selsted et al., 1996).  In 
mammals β-defensins are one of the two main antimicrobial peptide families (Huttner et 
al., 1998b).  They have been found to be expressed from both epithelial and circulating 
phagocytic cells (Huttner et al., 1998a).  It is believed that β-defensins help to protect the 
respiratory tract and other mucosal surfaces.  The first member of the β-defensin family 
of mammalian antibacterial peptides discovered was Tracheal Antimicrobial Peptide 
(TAP) (Diamond et al., 2000).  The 38 amino acid residue-long TAP was found to be 
expressed from the ciliated epithelium of the bovine trachea.  Researchers found that it   35
had a broad spectrum of antibacterial activity.  Furthermore, in vitro studies showed that 
cultured tracheal cells exposed to either bacteria or bacterial LPS could greatly increase 
TAP mRNA synthesis (Diamond et al., 2000).  All cattle produce at least 15 different 
forms of β-defensins (Huttner et al., 1998a).  Bactenecins, another antimicrobial peptide, 
have also been found in bovine neutrophils (Boman et al., 1991).   
  In addition to β-defensins, the cathelicidins are one of the two principle 
antimicrobial peptide families in mammals (Huttner et al., 1998b).  Cathelicidins have 
been found in humans, mice, pigs, cattle, and sheep (Hancock et al., 1998, Huttner et al., 
1998b).  Neutrophil precursor (myeloid) cells of mammals contain the precursor 
polypeptide (Hancock et al., 1998).  The polypeptide is made up of a conserved NH2-
terminal precursor (cathelin) domain of about 100 amino acid residues, immediately 
followed by an α-helical antimicrobial peptide of about 23 to 38 amino acid residues.  
The mature peptides are only processed after the neutrophil becomes activated (Storici et 
al., 1996).  The secondary structure of cathelicidin-derived antimicrobial peptides is a 
cationic, amphipathic, α-helical NH2-terminus and a straight hydrophobic COOH-
terminus (Skerlavaj et al., 1996).  Circular dichroism has shown that less than 20% of the 
structure is in an α-helical conformation, while 30 to 50% of the structure is in an 
extended (tail) conformation (Storici et al., 1996).  Unlike cecropins, cathelicidins 
contain four cysteine residues which form two disulfide bonds. 
  More than 20 cathelicidins have been identified (Skerlavaj et al., 1996).  Not only 
have they been shown to have antibacterial properties, but some have been shown to bind 
bacteria LPS (Hancock et al., 1998).  Two bovine cathelicidins were shown to have 
potent and broad spectrum antibacterial activity in vitro (Skerlavaj et al., 1996).    36
However, both were cytotoxic to human erythrocytes and neutrophils at high 
concentrations. 
  Lactoferricins are relatively new antimicrobials which are cleaved from the NH2-
terminus of lactoferrin, an iron-binding protein (Haukland et al., 2001).  Lactoferricin B 
is derived from acid-pepsin hydrolysis of bovine lactoferrin (Haukland et al., 2001, Jones 
et al., 1994).  The primary structure contains 25 amino acid residues, many of them 
hydrophobic and cationic.  Primary sequence analysis suggests that the peptide may 
interact with biological membranes (Haukland et al., 2001).  Lactoferricin B is believed 
to disrupt the cytoplasmic membrane of bacteria.  Researchers have shown that 
lactoferricin B is rapidly bactericidal against a broad spectrum of bacteria (Jones et al., 
1994).  However, Proteus ssp., Pseudomonas cepacia, and Serratia ssp. were resistant.  
Furthermore, variables such as increased ionic strength, increased bacterial inoculum, 
acid pH, the addition of 5% whole cow’s milk, and increasing concentrations of mucin all 
inhibited or reduced lactoferricin B activity (Jones et al., 1994).  Results indicate that this 
peptide is only transiently active in vivo. 
Cecropin B as a Novel Antibiotic 
  As previously mentioned, antibiotic resistant strains of M. haemolytica 1:A are 
becoming more common (Hartman et al., 1993).  Increasing patterns of antibiotic 
resistance, in this and many other pathogens, are fueling a growing public concern for the 
use of antibiotics in food animals.  It may be beneficial to find novel antibacterial agents 
that are not susceptible to existing mechanisms of resistance.  The very potent broad 
spectrum antibacterial activity of cecropin B makes it a likely candidate to prevent and/or   37
treat infection.  Since it is highly effective against Gram-negative bacteria (Vaara et al., 
1994), it may be useful for eradication of pathogens from mucosal surfaces. 
  One study showed that cecropins in general are 10 to 30 times (molar terms) more 
potent against E. coli and Pseudomonas aerugenosa than defensins and magainins (Vaara 
et al., 1994).  Septic shock is primarily induced by endotoxin (LPS) secreted by Gram-
negative bacteria.  In an effort to determine the efficacy of antimicrobial agents at 
reducing variables associated with septic shock, researchers found cecropin B to be very 
effective (Giacometti et al., 2001).  Researchers used mono-dose treatments of cecropins 
A, B and P1 in rats infected with 2x10
10 colony forming units (CFU) of E. coli.  Cecropin 
B was found to be the most effective at preventing bacterial growth,  endotoxemia and 
mortality (Giacometti et al., 2001).  While some antibiotics can induce endotoxemia, 
cecropin B possesses important anti-endotoxemia activity by binding LPS.  This and 
other studies have demonstrated the possible use of antibacterial peptides as topical or 
injectible antibiotics against pathogens otherwise resistant to conventional antibiotics 
(Hancock et al., 1998).  The ability of cecropin B to effectively inhibit bacterial 
colonization and neutralize endotoxin further exemplifies its usefulness as a novel 
antibiotic.  However, cost of production may limit this peptide’s practical uses.  The most 
cost efficient peptide synthesis methods employed at the present time are still 
unreasonably expensive (Hancock et al., 1998).   
  One possible cost-effective approach would be to transfer the cecropin B gene 
into the species of interest and let the recipient’s biosynthesis mechanisms synthesize the 
peptide.  Most transgenic studies involving the cecropin B gene or genes of cecropin B 
homologues and analogues have been performed in plants such as tobacco, potatoes, rice   38
and tomatoes.  These studies have met with varying success, but suggest that cecropin B 
can be expressed at the RNA and protein level, while transgenic plants display some 
resistance to bacterial infection (Hancock et al., 1998).  Florack et al. used several 
different cecropin B gene constructs made for either expression in the cytosol or for 
secretion (Florack et al., 1995).  Plants transfected with a gene construct containing insect 
signal peptide expressed higher levels of cecropin B mRNA than gene constructs lacking 
a NH2-terminal signal peptide.  The highest cecropin B mRNA expression levels were 
seen in plants transfected with a gene construct containing a plant-gene-derived signal 
peptide (Florack et al., 1995).  Even though cecropin B mRNA could be detected, the 
plants were still not resistant to bacterial wilt and bacterial wildfire.  Furthermore, 
researchers could not detect the cecropin B peptide.  Further analysis showed that the 
peptide was most likely degraded by endogenous proteases (Florack et al., 1995).  
Cecropins can effectively lyse most Gram-positive and Gram-negative bacteria at very 
low concentrations of 0.1 to 5 µM, but degradation due to host peptidases can be a very 
limiting factor (Sharma et al., 2000).  To address this problem, researchers fused the 
coding sequences of mature cecropin B to the signal peptide sequence of the rice 
chitinase gene which is known to direct the secretion of chitinase gene product into the 
intercellular spaces of rice (Sharma et al., 2000).  After transfecting rice plants with this 
gene construct they were able to detect expressed cecropin B mRNA, high levels of 
intercellular cecropin B peptide, and enhanced resistance to bacterial leaf blight.  In yet 
another study, researchers used a synthetic NH2-terminus-modified cecropin-mellitin 
peptide chimera to transfect potato plants (Osusky et al., 2000).  Using polymerase chain 
reaction (PCR) and DNA sequencing they were able to confirm stable incorporation of   39
the gene construct.  Cecropin-mellitin chimera mRNA expression was confirmed by 
reverse transcriptase-PCR (RT-PCR), and they were able to recover active peptide 
(Osusky et al., 2000).  Following highly stringent challenges these transgenic potato 
plants exhibited potent bacterial resistance.  It seems that researchers are well on the path 
of developing bacterial resistant transgenic plants. 
  Very few studies are available describing transgenic mammals expressing 
cecropin B or cecropin B-like peptides.  In a preliminary report researchers using a 
cecropin B analog to transfect mice found the mice to be resistant to Brucella abortus, a 
bovine pathogen (Hagius et al., 1996).  There are many indications that the transgenic 
approach may be useful in enhancing bacterial resistance in food animals, thereby 
reducing the use of conventional antibiotics. 
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CHAPTER 2 
IN VITRO SUSCEPTIBILITY OF A VIRULENT STRAIN OF MANNHEIMIA 
HAEMOLYTICA 1:A TO CECROPIN B 
 
 
Introduction 
 
Mannheimia haemolytica 1:A is a gram-negative bacterium generally regarded as the 
cause of bovine pneumonic pasteurellosis.  While M. haemolytica 1:A can be a normal resident 
of the bovine nasal passage, under times of stress, the bacterium proliferates in the upper 
respiratory tract (URT).  The use of antibiotics to treat pneumonic pasteurellosis has been 
generally successful (Frank, 1986).  However, M. haemolytica 1:A is developing an increasing 
pattern of resistance to drugs commonly used to treat the disease (Hartman and Geryl, 1993).  
Due to an increasing pattern of antibiotic resistance among many species of bacteria, public 
concern for the use of antibiotics in food animals is once again on the rise (Ferber, 2003).  With 
the occurrence of antibiotic resistant strains of bacteria, the appropriate use of antibiotics should 
include exposing M. haemolytica 1:A to sufficient concentrations of the antimicrobial agents for 
an appropriate duration as to minimize the development of resistant strains (Watts et al., 1994). 
  Cecropins are small, strongly basic proteins, which have a broad spectrum of 
bactericidal activity (Steiner et al., 1988) but are unable to disrupt eukaryotic cells (Boman et al., 
1991).  This clearly implicates their possible usefulness as novel antibiotics.  Cecropins have 
been shown to have direct action on bacterial membranes
 (Steiner et al., 1988), although the 
exact mechanisms are not yet fully understood.  Primary membrane attack is believed to be the 
cause of both Gram-positive and Gram-negative bacteria lysis (Steiner et al., 1988).  
Furthermore, binding sufficient amounts of cecropin to form a monolayer is necessary to modify 
the bacterial membranes.  Although cecropin B has a broad spectrum of activity against both   41
Gram-positive and Gram-negative bacteria, the latter are generally more susceptible (Moore et 
al., 1996).  Cecropin B initially interacts with the highly anionic outer membrane glycolipid, 
LPS, of Gram-negative organisms (Hancock et al., 1998).  The peptide then accesses the 
cytoplasmic membrane by local disruption of the outer membrane.   
Cecropin B was chosen for its availability and efficacy.  Studies have demonstrated the 
possible use of cecropin B as topical or injectable antibiotics against pathogens otherwise 
resistant to conventional antibiotics (Hancock et al., 1998).  It has been shown to possess the 
broadest bactericidal activity of the cecropin family (Chen et al., 1997).  The purpose of this 
study was to determine, in vitro, the antibacterial efficacy of cecropin B for a virulent strain of 
M. haemolytica 1:A.  Also, an attempt was made to determine the stability of cecropin B activity 
in the bovine nasal mucosa.  
Materials and Methods 
Preparation of Virulent M.  haemolytica 1:A Inoculum   
A preparation of a virulent M. haemolytica 1:A strain, lyophilized in skim milk, was 
reconstituted with 1 ml of sterile distilled H2O.  The suspension was streaked for isolation on 
yeast blood agar plates with 10% horse serum (10% YBP) and allowed to incubate for 18-24 
hours at 37
oC in a candle jar (5% CO2 atmosphere).  Bacterial growth was visually identified as 
M. haemolytica 1:A.  Isolated colonies were added to 10 ml of sterile Brain Heart Infusion (BHI) 
broth (Becton Dickinson and Co., BD Microbiology Systems, Sparks, MD) and incubated for an 
additional 18-24 hours at 37
oC.   A 100 µl aliquot of this culture was added to 10 ml of sterile 
BHI broth and incubated for another 8 hours at 37
oC.   The concentration was adjusted to 
approximately 8 x 10
6 colony-forming units (CFU) with sterile BHI broth. 
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Minimum Inhibitory Concentration (MIC)   
MICs were determined according to the procedures outlined by the National Committee 
for Clinical Laboratory Standards (NCCLS).  The broth microdilution method was performed in 
96-well plates.  BHI broth was used instead of the recommended Mueller-Hinton broth 
(NCCLS).  Although Mueller-Hinton broth is acceptable for the growth of M. haemolytica 1:A, 
BHI broth was chosen to meet specific growth requirements and provide consistent growth.  Test 
wells containing two-fold dilutions of cecropin B were incubated in triplicate.  Each test well 
was inoculated with a final concentration of 5 x 10
4 CFU of M. haemolytica 1:A per well.  Each 
plate included positive control (no cecropin B, in triplicate) and negative control (no M. 
haemolytica 1:A) wells.  Due to the expense of Cecropin B (Sigma, Sigma-Aldrich Corporation, 
St. Louis, MO), tetracycline was used first, to standardize the assay.   Results were read both 
visually and with a Dynatech plate reader (Dynatech Laboratories Inc., Chantily, VA) at 16, 20 
and 24 hours of incubation.  The MIC was determined as the lowest concentration of the 
antimicrobial agent, which completely inhibited visible growth. 
Statistical Analysis  
Data were analyzed by use of two-factor ANOVA. 
The Stability of Cecropin B in the Bovine Nasal Mucosa 
To determine the stability of cecropin B in the bovine nasal mucosa, nasal secretions 
were collected using a modified 1 ml pipette bent at a 45
o angle approximately 4 to 5 cm from 
the end and attached to 3 mm diameter tubing that was connected to a 10 ml evacuated tube by a 
16 gauge needle.  A vacuum was created in the tube using an electric vacuum pump (General 
Electric Model 5KH35GN106CX, Benton Harbor, MI).  The pipette was inserted into each 
nostril to aspirate nasal secretions.  Five milliliters of sterile Dulbecco’s phosphate buffered   43
saline (duPBS) (pH7.2) was then aspirated through the pipette and collected along with mucus in 
the tube.  Nasal secretions were pooled from three calves.   
For the assay, 200 µl of M. haemolytica 1:A culture (mid-log-phase, final concentration 
of 10
5 CFU/ml) were mixed with 200 µl of cecropin B diluted in sterile PBS (pH 7.2) (8 µg/ml), 
as well as 200 µl of cecropin B diluted in pooled bovine nasal secretions  (8 µg/ml).  The final 
concentration of cecropin B in each culture was 4 µg/ml.  The two assay cultures were allowed 
to incubate at 37
oC.  At time intervals 0, 20, and 60 minutes, the assay cultures were diluted 10
-1 
to 10
-6, and plated on 10% YBP.  The plates were allowed to incubate at 37
oC and colonies were 
counted at 24 hours.  The time intervals of 0, 20, and 60 minutes were arbitrarily chosen.   
Results 
When visually observed, the MIC of tetracycline was 32 µg/ml as seen in Table 2.1.  At 
16 hours M. haemolytica 1:A growth, as determined by optical density at 630 nm, in the positive 
control wells was significantly higher (P<0.05) than growth in all wells containing tetracycline 
(Figure 2.1).  At 20 and 24 hours M. haemolytica 1:A growth in the positive control wells was 
significantly higher (P<0.05) than growth at all concentrations of tetracycline except the lowest 
concentration of 2 µg/ml.  Growth measured in these wells was equal to the growth measured in 
the positive control wells.  Growth measured for inhibiting concentrations 128, 64, and 32 µg/ml 
was not significantly different between 16, 20, or 24 hours of incubation.  Wells containing these 
inhibiting concentrations did not show a significant increase or decrease from 16 to 24 hours. At 
16 hours of incubation in the wells where growth was not inhibited, concentrations 16, 8, 4, and 
2 µg/ml, growth significantly increased (P<0.05) as the concentration of tetracycline decreased.  
At 20 and 24 hours growth slightly decreased as the concentration of tetracycline decreased from   44
16 to 4 µg/ml and then increased significantly (P<0.05) as the concentration of tetracycline 
decreased from 4 to 2 µg/ml. 
Table 2.1.  Tetracycline susceptibility as determined by visual growth of M. haemolytica 1:A. 
 
  Tetracycline 
Concentration   
 Visual 
Growth   
(µg/ml)  16hr   20 hr  24hr
128  -  -  - 
64  -  -  - 
32  -  -  - 
16  +  +  + 
8  +  +  + 
4  +  +  + 
2  +  +  + 
(+) control  +  +  + 
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Figure 2.1.  Tetracycline susceptibility of M. haemolytica 1:A as determined by optical density 
measured at 630 nm.  Optical densities sharing the same letter are not statistically different 
(P>0.05). 
 
When visually observed, the MIC of cecropin B was 2 µg/ml as seen in Table 2.2. At 16, 
20, and 24 hours, M. haemolytica 1:A growth, as determined by optical density at 630 nm, in the 
positive control wells and wells containing 1 µg/ml were significantly higher (P<0.05) than 
growth in the wells containing 128, 64, 32, 16, 8, 4, and 2 µg/ml of cecropin B (Figure 2.2).     45
Table 2.2.  Cecropin B susceptibility as determined by visual growth of M. haemolytica 1:A. 
 
Cecropin B 
Concentration   
Visual 
Growth   
(µg/ml)  16hr 20 hr  24hr
128  -  -  - 
64  -  -  - 
32  -  -  - 
16  -  -  - 
8  -  -  - 
4  -  -  - 
2  -  -  - 
1  +  +  + 
(+) control  +  +  + 
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Figure 2.2.  Cecropin B susceptibility of M. haemolytica 1:A as determined by optical density 
measured at 630 nm.  Optical densities sharing the same letter are not statistically different 
(P>0.05). 
 
Growth measured for concentrations, 128, 64, 32, 16, 8, 4, and 2 µg/ml, was not significantly 
different from 16 to 24 hours.  Wells containing these inhibiting concentrations of cecropin B did 
not show a significant increase or decrease from 16 to 24 hours.  Growth in wells containing 1 
µg/ml significantly increased between the 16 and 20 hour readings and again between the 20 and 
24 hour readings.  At 16 hours of incubation, growth measured in wells containing 1 µg/ml was 
significantly lower (P<0.05) than growth measured in the positive control wells.  By 20 hours of   46
incubation there was no significant difference (P<0.05) between these wells.  At 24 hours of 
incubation growth in the wells containing 1 µg/ml of cecropin B was significantly higher than 
that of the positive control wells.  Growth measured in the positive control wells did not increase 
or decrease from 16 to 24 hours of incubation. 
  When diluted in PBS (pH 7.2), a 4 µg concentration of cecropin B completely inhibited 
approximately 10
5 CFU of M. haemolytica 1:A within 20 minutes (Figure 2.3).  No change was 
observed at 60 minutes of incubation.  When diluted in pooled bovine nasal secretions, a 4 µg 
concentration of cecropin B again completely inhibited approximately 10
5 CFU of M. 
haemolytica 1:A within 20 minutes (Figure 2.4).  Again no change was observed at 60 minutes 
of incubation. 
Discussion 
To provide protection against pneumonic pasteurellosis, M.  haemolytica 1:A should not 
be allowed to colonize the upper respiratory tract.  The use of an effective antibiotic to inhibit the 
rapid colonization of M. haemolytica 1:A in the nasopharynx should reduce the occurrence of 
pneumonic pasteurellosis in cattle arriving at the feedlots.  There have been very few studies 
aimed at the use of antibiotics to eliminate colonization of the nasal passage.  However, in one 
such study the use of oxytetracycline or feeding chlortetracycline at the feedlots did not reduce 
or eliminate the colonization of M. haemolytica 1:A in the nasopharynx (Frank et al., 2000b).  In 
calves experimentally infected with M. haemolytica 1:A, tilmicosin was effective in alleviating 
clinical signs and pathology findings of pneumonic pasteurellosis as well as the presence of 
viable organisms in the lung (Morck et al., 1997).  Furthermore, the lung could be protected for 
up to 72 hours with concentrations well above the MIC for M. haemolytica 1:A (Morck et al., 
1997).  Researchers have also shown that a single dose of tilmicosin was more effective   47
Cecropin B 
in PBS
0
1
2
3
4
5
6
02 0 6 0
min
L
o
g
1
0
 
C
F
U
/
m
l
 
Figure 2.3.  Antibacterial activity of cecropin B against M. haemolytica 1:A.  Mid-log-phase M.  
haemolytica 1:A cells (10
5 CFU/ml) were incubated with cecropin B (4 µg/ml) for 60 minutes at 
37°C. 
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Figure 2.4.  Antibacterial activity of cecropin B against M. haemolytica 1:A in the presence of 
pooled bovine nasal secretions.  Mid-log-phase M.  haemolytica 1:A cells (10
5 CFU/ml) were 
incubated with cecropin B (4 µg/ml) for 60 minutes at 37°C. 
 
at reducing mortality due to pneumonic pasteurellosis than ceftiofur, oxytetracycline, or 
trimethoprim-sulfadoxine (Shyrock et al., 1996).  In other studies focused on decreasing M. 
haemolytica 1:A colonization in the nasopharynx, both tilmicosin and florfenicol were shown to 
be effective (Frank et al., 2000a, Frank et al., 2002).  Both antibiotics inhibited M. haemolytica 
1:A colonization in the nasal passage for up to several days (Frank et al., 2002). 
  In this study the MIC of tetracycline was determined as a quality control.  The MIC was 
measured to be 32 µg/ml.  This value is consistent with that obtained in a recent study which   48
showed the MIC of tetracycline for 90% of the M. haemolytica 1:A isolates tested to be 32 µg/ml 
(Watts et al., 1994). 
Results of the present study indicate that cecropin B is very effective in inhibiting this 
virulent strain of M. haemolytica 1:A.  Growth of this isolate was inhibited at the MIC of 2 
µg/ml.  However, only one isolate was tested.  These results may warrant further testing with 
larger numbers of isolates to more accurately determine susceptibility breakpoints for M. 
haemolytica 1:A.  
The very potent broad spectrum antibacterial activity of cecropin B makes it a likely 
candidate to prevent and/or treat infection.  Since it is highly effective against Gram-negative 
bacteria (Vaara et al., 1994), it may be useful for eradication of pathogens from mucosal 
surfaces.  One problem to this approach is that the peptide may be degraded by endogenous 
proteases (Florack et al., 1995, Sharma et al., 2000).  While cecropin B can effectively lyse 
bacteria at very low concentrations, degradation can be a limiting factor.  Although proteolytic 
enzymes in the bovine nasal mucosa may degrade the peptide and inhibit antibacterial activity, 
no inhibition was observed by incubating cecropin B in bovine nasal secretion.  Furthermore, 
cecropin B was able to completely inhibit M. haemolytica 1:A growth within 20 minutes of 
incubation.  The ability of cecropin B to effectively inhibit bacterial colonization as well as 
neutralize endotoxin further exemplifies its usefulness as a novel antibiotic.  However, cost of 
production may be yet another factor that will limit this peptide’s practical uses.  The most cost 
efficient peptide synthesis methods employed at the present time are still unreasonably expensive 
(Hancock et al., 1998).   Therefore, the use of cecropin B as a topical or injectable antibiotic may 
not be a suitable approach. 
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CHAPTER 3 
 
TRANSGENIC EXPRESSION OF CECROPIN B IN THE NASAL PASSAGE OF 
CATTLE CHALLENGED WITH A VIRULENT STRAIN OF MANNHEIMIA 
HAEMOLYTICA 1:A 
 
Introduction 
The major etiologic agent of bovine pneumonic pasteurellosis is Mannheimia 
haemolytica 1:A (Dalgleish, 1990, Frank, 1986).  Vaccines which provide cattle with 
effective and consistent immunity to pneumonic pasteurellosis are not yet available.  
Most veterinarians rely on antimicrobial agents to treat this disease.  However, studies 
have shown M. haemolytica 1:A to have an increasing pattern of resistance to many of 
the commonly used antibiotics (Hartman et al., 1993).   
The diapausing pupae of the saturniid Hyalophora cecropia, also known as the 
giant silk moth, respond to bacterial infection with the synthesis of highly effective 
antibacterial peptides (Boman et al., 1991).  Although the moth synthesizes three 
different classes of antibacterial peptides, the cecropins have the most effective 
bactericidal activity (Boman et al., 1987, Chen et al., 1997).  Cecropin B has a broad 
spectrum lytic activity, and is very effective against Gram-negative organisms (Vaara et 
al., 1994).  
The very potent antibacterial activity of cecropin B makes it a likely candidate to 
prevent and/or treat infection.  Since it is highly effective against Gram-negative bacteria, 
it may be useful for eradication of pathogens from mucosal surfaces.  Few studies are 
available describing transfected mammals expressing cecropin B or cecropin B-like 
peptides; however there are many indications that a transgenic or gene therapeutic 
approach may be useful in enhancing bacterial resistance in cattle.     50
Materials and Methods 
Transposon-based Plasmid Vector 
A transposon-based plasmid vector containing the cecropin B gene was obtained 
from Dr. Richard Cooper (Cooper, 1998, Cooper and Enright, 1996). This plasmid 
contains the cecropin B gene linked to an acute phase response promoter (APR) was 
inserted between 2 transposon insertion sequences.  The plasmid also contained the Ptac 
promoter for the transcription of transposase (Ats).  Ats was also encoded on the plasmid.  
The plasmid was delivered by aerosol while complexed to a transfection reagent 
(Superfect
®, Qiagen, Inc., Valencia, CA).  Superfect
® is designed to deliver DNA to the 
nucleus of eukaryotic cells.  It is a specifically designed activated dendrimer. The reagent 
complexes with DNA and arranges it in compact structures to ease entry into the cell.  
Superfect
® complexed with the plasmid possesses a net positive charge, which allows it 
to bind negatively charged cell surface receptors. The reagent also stabilizes plasmid 
DNA inside the cell by pH inhibition of lysosomal nucleases.  The plasmid was 
complexed with Superfect
® at a 1:3 ratio.   
The aerosol was administered using methods derived from a previous study 
(Brennan et al., 1998).  The delivery system for the aerosol was a modified siphon-feed 
gun (Sears Craftsman Model 491.167060, Hoffman Estates, IL.) with a 7 cm piece of 
tubing attached to the nozzle.  The gun was attached to a nitrogen tank and 20 kg of 
pressure was used to intranasally aerosolize the suspension.  All personnel involved in the 
DNA delivery were wearing disposable coveralls, disposable latex gloves and HEPA 
filtered respirators to prevent accidental exposure.  The disposable coveralls and latex 
gloves were properly disposed as biohazardous waste.   51
Experiment I 
  Seven (n=7) 300-500 lbs. crossbred beef calves were brought to the Louisiana 
State University Veterinary Science Farm in Baton Rouge, LA and kept on pasture.  
Calves were randomly assigned to one of 2 groups.  One group was designated the 
treatment group (n=4), and the other was designated the control group (n=3).  The two 
groups were not isolated during the experiment.  Nasal swabs were collected from all 
calves prior to transfection. Each of the 4 treated calves were given 50 µg of DNA 
complexed with a transfection reagent (Superfect
®, Qiagen, Inc., Valencia, CA)  
suspended in 3 ml of sterile phosphate buffered saline (PBS) (pH 7.2) per nostril.  
Control calves were given only the transfection reagent suspended in 3 ml of sterile PBS 
(pH 7.2) per nostril.  Control calves were aerosolized first then allowed to return to the 
pasture. Next the treated calves were aerosolized and allowed to return to pasture.  Nasal 
swabs were collected on 0, 3, 7, 14, and 21 days post transfection and submitted for DNA 
polymerase chain reaction (PCR).   
Experiment II 
Eight (n=8) 300-500 lbs. crossbred beef calves were brought to the Louisiana 
State University Veterinary Science Farm in Baton Rouge, LA and kept on pasture.  
Calves were randomly assigned to one of 2 groups.  One group was designated the 
treatment group (n=4), and the other was designated the control group (n=4).  The two 
groups were isolated throughout the experiment.  Nasal swabs, nasal aspirates and blood 
were collected from all calves prior to transfection.  Each of the 4 treated calves were 
given 25 µg of DNA complexed with  a transfection reagent (Superfect
®, Qiagen, Inc., 
Valencia, CA) suspended in 3 ml of sterile PBS (pH 7.2) per nostril.  Control calves were   52
given only the transfection reagent suspended in 3 ml of sterile PBS (pH 7.2) per nostril.  
Control calves were aerosolized first then allowed to return to the pasture. The treated 
calves were aerosolized one at a time, with that calf being the only calf allowed in the 
chute at the time.  Control calves were isolated from this event.  All 8 (treated and 
control) calves were then inoculated intranasally with 2 x 10
7 to 2 x 10
8 colony forming 
units (CFU) of a virulent strain of M. haemolytica 1:A suspended in 3 ml of sterile 
Dulbecco’s PBS (duPBS) (pH 7.2) (Sigma Chemical Co., St. Louis, MO) per nostril. 
Following the inoculation, groups were trucked separately 100 miles for 3 hours to stress 
them.  Serum, nasal aspirates, and nasal swabs were collected on 0, 3, 7, 14, 21, and 28 
days post transfection/challenge.  Samples were analyzed by bacterial culture, real-time 
PCR, real-time reverse transcriptase (RT) PCR, and ELISA.  All samples on day 0 were 
collected prior to any calf receiving the DNA aerosol.  All calves were examined daily 
for clinical signs of respiratory disease to eliminate the possibility of an adventitious 
infection. 
Experiment III 
Twelve (n=12) 300-500 lbs. crossbred beef calves were brought to the Louisiana 
State University Veterinary Science Farm in Baton Rouge, LA and kept on pasture.  
Calves were randomly assigned to one of 3 groups.  Two groups were designated the 
treatment groups (n=4 each), and the other was designated the control group (n=4).  The 
three groups were again isolated throughout the experiment.  Nasal swabs, nasal 
aspirates, and blood were collected from all calves prior to transfection.  Each of the 4 
treated calves in one group were given 50 µg of DNA complexed with a transfection 
reagent (Superfect
®, Qiagen, Inc., Valencia, CA) suspended in 3 ml of sterile PBS pH 7.2   53
per nostril, as previously described.  Each of the 4 treated calves in the other treatment 
group were given 100 µg of DNA complexed with a transfection reagent (Superfect
®, 
Qiagen, Inc., Valencia, CA) suspended in 3 ml of sterile PBS (pH 7.2) per nostril.  
Control calves were given only the transfection reagent suspended in 3 ml of sterile PBS 
(pH 7.2) per nostril.  Control calves were aerosolized first then allowed to return to the 
pasture. The treated calves were aerosolized one at a time, with that calf being the only 
calf allowed in the chute at the time.  The two treated groups were aerosolized on 
different days.  Control calves were isolated from this event.  All 12 (treated and control) 
calves were inoculated intranasally with 2 x 10
7 to 2 x 10
8 CFU of a virulent strain of M. 
haemolytica 1:A  suspended in 3 ml of sterile duPBS (pH 7.2) (Sigma Chemical Co., St. 
Louis, MO) per nostril. Following the inoculation, groups were trucked separately 100 
miles for 3 hours to stress them.  Serum, nasal aspirates and nasal swabs were collected 
on 0, 3, 7, 14, 21, and 28 days post transfection/challenge.  Samples were analyzed by 
bacterial culture, real-time PCR, real-time RT-PCR, and ELISA.  All samples on day 0 
were collected prior to any calf receiving the DNA aerosol.  All calves were examined 
daily for clinical signs of respiratory disease to eliminate the possibility of an 
adventitious infection. 
Preparation of a Virulent M. haemolytica 1:A Strain 
A preparation of a virulent M. haemolytica 1:A strain, lyophilized in skim milk, 
was reconstituted with 1 ml of sterile distilled H2O.  The suspension was streaked for 
isolation on yeast blood agar plates with 10% horse serum (10% YBP) and allowed to 
incubate for 18-24 hours at 37
oC in a candle jar (5% CO2 atmosphere).  Bacterial growth 
was visually identified as M. haemolytica 1:A.  Isolated colonies were picked and added   54
to 1 ml of sterile duPBS (pH 7.2) until the solution became turbid.  The solution was then 
used to streak sixteen 10% YBP confluently which were incubated for an additional 18-
24 hours at 37
oC.  Bacterial growth was harvested using a sterile cotton swab and 
suspended in 20 ml of sterile duPBS (pH 7.2).  The concentration was adjusted to 
approximately 2 x 10
7 to 2 x 10
8 CFU with sterile duPBS (pH 7.2). 
Nasal Aspirate Collection 
  Nasal aspirates were collected using a modified 1 ml pipette bent at a 45
o angle 
approximately 4 to 5 cm from the end and attached to 3 mm diameter tubing that, in turn, 
was connected to a 10 ml evacuated tube by a 16 gauge needle.  A vacuum was created in 
the tube with a vacuum pump (General Electric Model 5KH35GN106CX, Benton 
Harbor, MI).  The pipette was inserted into each nostril to aspirate nasal secretions.  Five 
milliliters of sterile duPBS (pH 7.2) were then aspirated through the pipette and collected 
along with mucus into the tube. 
Serum Sample Collection 
Blood samples were collected into plain evacuated tubes, and allowed to clot at 
room temperature (approx. 20
o C) for 2 hours.  Then they were centrifuged at 850 x g for 
20 minutes (Beckman TJ-6 Centrifuge, Palo Alto, CA). 
PCR Amplification 
Total DNA was purified from nasal swabs collected on days 0, 3, 7, 14 and 21 of 
experiment I using Qiagen DNeasy® extraction kits (Qiagen, Inc., Valencia, CA).  
Forward and reverse primers were designed to target the cecropin B gene.  The forward 
primer Vec1 (5’-CTACGCTGTAACATCCAAACT-3’) and reverse primer Vec2 (5’-  55
CGCTTTGGCTTCGCCTAAAA-3’) were selected.  These primers amplify a 946-bp 
region of the cecropin B gene (bases 401 to 1346, GenBank accession no. X07404).  The 
reaction mixture contained a 50 µM concentration of the forward primer and a 50 µM 
concentration of the reverse primer.  PCR’s were performed using PTC-100 
Programmable Thermal Controller (MJ Research, Inc., Watertown, MA).  The thermal 
cycler program used was 96ºC for 5 minutes, then 35 cycles at 96ºC for 30 seconds, 58ºC 
for 30 seconds, and 72ºC for 30 seconds, followed by 72ºC for 5 minutes.  All PCR 
products were electrophoresed on a 1% agarose gel in Tris-acetate-EDTA (TAE) buffer, 
and the DNA was visualized by ethidium bromide staining under UV fluorescence.   
Quantitative Real-time PCR and RT-PCR 
Forward and reverse primers as well as a fluorescent probe were designed to 
target the cecropin B gene.  The forward primer CB1-5’ (5’-
TGGGTCGCAACATCAGAAAC-3’), reverse primer CB1-3’ (5’-
CCTAGCGCTTTGGCTTCG-3’), and fluorescent CB gene probe (5’-FAM-
TCGCCGGTCCAGCCTTGACAATA-TAMRA-3’) were selected.  These primers 
amplify a 76-bp region inside the transcribed region of the cecropin B gene (bases 1276 
to 1334, GenBank accession no. X07404).  The reaction mixture contained a 20 µM 
concentration of the forward primer, a 20 µM concentration of the reverse primer, and a 7 
µM concentration of the fluorescent probe.  Real-time PCR, RT-PCR, and probe 
detection were performed using an ABI PRISM 7900 Sequence detection system (PE 
Applied Biosystems, Perkin-Elmer, Foster City, CA).  The standard real-time PCR 
thermal cycler program used was 50ºC for 2 minutes, 95ºC for 10 minutes, 40 cycles at 
95ºC for 15 seconds, and 60ºC for 1 minute.  The standard real-time RT-PCR thermal   56
cycler program used an additional step of 48ºC for 30 minutes to convert RNA into 
cDNA. 
  Total DNA was purified from nasal swabs collected on days 0, 3, 7, 14, 21 and 28 
of experiments II & III using Qiagen DNeasy® extraction kits (Qiagen Inc., Valencia, 
CA).  The quantitative results were based on a 5-fold dilution of plasmid DNA.  Each 
total genomic DNA extraction was normalized by using an endogenous control (the 
eukaryotic 18s rRNA gene) as an active reference to adjust for differences in the amount 
of total DNA added to each reaction mixture.  For an individual calf the relative level of 
cecropin B DNA in each sample (days 3, 7, 14, 21, and 28) was determined as a ratio 
compared to day 0 (the calibrator).  Results were expressed as arbitrary units (AU). 
Total RNA was purified from nasal aspirates collected on days 0, 3, 7, 14, 21, and 
28 of experiments II & III using Qiagen RNeasy® extraction kits (Qiagen Inc., Valencia, 
CA).  The quantitative results were based on a 5-fold dilution of bovine RNA containing 
cecropin B mRNA.  Each total genomic RNA extraction was normalized by using an 
endogenous control (the eukaryotic 18s rRNA gene) as an active reference.  In order to 
adjust for differences in the amount of total RNA added to each reaction mixture.  For an 
individual calf the relative level of cecropin B mRNA in each sample (days 3, 7, 14, 21, 
and 28) was determined as a ratio compared to day 0 (the calibrator).  Results were 
expressed as arbitrary units (AU). 
Bacterial Culture 
Nasal aspirates collected from 0, 3, 7, 14, 21, and 28 days post 
transfection/challenge were analyzed by bacterial culture.   Aliquots of these samples 
were diluted in sterile duPBS (pH 7.2) to 1:10, 1:100, and 1:1000 of the original   57
concentration.  Within one to four hours after collection, small amounts (0.1 ml) of each 
dilution and of the undiluted sample were directly streaked onto separate 1% YBP (Difco, 
Becton, Dickinson and Co., Sparks, MD.).  The plates were allowed to incubate in a 5% 
CO2 atmosphere for up to 72 hours at 37
oC.  The plates were observed for bacterial 
growth every 24 hours.  Isolated colonies of M. haemolytica 1:A as well as the calves’ 
bacterial flora were counted, identified, and recorded. 
Small amounts (0.1 ml) of the undiluted sample were inoculated into Difco 
thioglycollate enrichment medium (Becton, Dickinson and Co., Sparks, MD.) plus 0.1% 
horse serum.  The thioglycollate tubes were allowed to incubate for up to 72 hours at 
37
oC.  The tubes were observed for bacterial growth every 24 hours.  Observed growth 
was then recorded and streaked onto 1% YBP, which were incubated in a 5% CO2 
atmosphere for 24 hours at 37
oC.  
Suspected M. haemolytica 1:A colonies were first identified on the basis of 
colonial morphology.  These representative colonies were then streaked onto manitol salt 
and McConkey agar plates as well as triple sugar iron (TSI), citrate, and urea slants 
(Difco, Becton, Dickinson and Co., Sparks, MD.).  Smears of these representative 
colonies were also Gram (Difco, Becton, Dickinson and Co., Sparks, MD.) stained.  M. 
haemolytica 1:A colonies were identified on the basis of morphology, cultural, and 
biochemical characteristics of the isolates in pure culture as well as by the presence of  
hemolysis, agglutination, and oxidase (Difco, Becton, Dickinson and Co., Sparks, MD.) 
test.  All findings were recorded. 
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Detection of Cecropin B by ELISA 
To test for cecropin B in nasal aspirates collected from days 0, 3, 7, 14, 21, and 28 
post transfection/challenge of experiment III, flat bottom wells of Immunolon 1 96-well 
microtitration plates (Dynatech Laboratories, Chantilly, VA) were coated with 100 µl of 
a 1:2 dilution of each nasal aspirate in 0.05 M sodium carbonate buffer (.03 M NaHCO3 
and .02 M NaCO3, pH 9.6) and incubated overnight at 4
oC for fixation.  Serial dilutions 
of a positive control nasal aspirate spiked with 2 µg/ml of cecropin B were included on 
each plate.  The positive controls were serially diluted 1:2 to 1:256 (2 µg/ml to 0.015625 
µg/ml).  Also included on each plate were several negative control nasal aspirates which 
were diluted 1:2.  Plates were washed 3 times with PBS (pH 7.2) containing 0.05% (v/v) 
Tween 20 (PBST).  Rabbit anti-cecropin B serum (obtained from Dr. William Todd, LSU 
Dept. of Vet. Science, Baton Rouge, LA.) diluted 1:200 in PBST was added to each well 
and incubated 1.5 hours at room temperature.  After washing 3 times with PBST, the 
plates were incubated 1.5 hours with 100 µl of alkaline phosphate-conjugated anti-rabbit 
IgG (Kirkegaard and Perry, Gaithersberg, MD) diluted 1:1000 in PBST.  The plates were 
washed 3 times with PBST and color was developed by adding 100 µl of substrate buffer 
containing 1 mg/ml p-nitrophenyl phosphatase, 10% diethanolamine, and 5 mM MgCl2 
(pNPP) (pH 9.8) (Kirkegaard and Perry, Gaithersberg, MD).  The absorbance was read at 
405 nm in a microplate reader (Benchmark Plus microplate spectrophotometer, Bio-Rad 
Life Science, Hercules, CA).   
The amounts of cecropin B in nasal aspirates were determined using regression 
equations.  Using the serially diluted positive controls, log O.D. values were plotted 
against the log dilution, generating a regression equation for each plate.  Sample   59
concentrations were calculated by substituting its log O.D. value into the equation.  
Subtracting the mean concentration of the negative controls plus 2 times the standard 
deviation from the sample concentration resulted in a corrected cecropin B concentration.  
Only corrected cecropin B concentrations were reported. 
Detection of Antibodies Against M. haemolytica 1:A by ELISA 
A whole cell M. haemolytica 1:A antigen preparation was obtained using 
previously described methods (Brennan et al., 1998).  The whole cell M. haemolytica 1:A 
antigen was diluted 1:200, in 0.1 M sodium carbonate buffer (.06 M NaHCO3 and .04 M 
NaCO3).  The flat bottom wells of Immunolon 1 96-well microtitration plates were then 
coated with 100 µl of the antigen dilution.  The plates were wrapped in cellophane and 
incubated overnight at 4
oC for fixation.  After 24 hours of incubation, the plates were 
washed three times with dH2O + NaCl + Tween 20, then blocked with 100 µl NET buffer 
(0.1M NaCl, 1mM EDTA, and 10mM Tris, pH 8.0) plus 10% heat inactivated goat serum 
per well for 30 minutes at 37
oC.  The plates were washed as before and 100 µl of each 
serum sample, diluted 1:200 in NET + 10% goat serum, was added to the appropriate 
wells.  Serial dilutions of a positive control serum sample pooled from high titer calves 
were included on each plate.  The positive controls were serially diluted 1:200 to 
1:25,600.  Also included on each plate were several negative control serum samples 
which were diluted 1:200.  Plates were then incubated for 1 hour at 37
oC and washed as 
before. Antigen-antibody complexes were detected by adding 100 µl of horseradish 
peroxidase conjugated affinity purified goat anti bovine immunoglobulins IgG heavy & 
light chain, IgG1 heavy chain, IgG2 heavy chain, IgA-α chain, or IgM-µ chain 
(Kirkegaard and Perry, Gaithersberg, MD) diluted 1:750 in  NET + 10% goat serum per   60
well. Plates were again incubated for 1 hour at 37
oC and then washed.  100 µl of substrate 
2-2’azino-di-3-ethylbenzothiazolin sulfone-6 (ABTS) (Kirkegaard and Perry, 
Gaithersberg, MD) was added to each well and allowed to react at room temperature for 
ten minutes.  The reaction was stopped by the addition of 10% sodium dodecyl sulfate 
(SDS) (100 µl) per well.  Optical densities were read immediately with an ELISA plate 
reader at a wavelength of 405 nm.   
Antibody responses in nasal aspirates were also measured by ELISA similarly to 
serum samples with a few exceptions.  Microtitration plates were coated with antigen 
overnight as previously described.  Nasal aspirates were diluted 1:2 in NET + 10% goat 
serum.  Positive controls were serially diluted 1:2 to 1:256, and negative controls were 
diluted 1:2.   
Antibody titers for serum and nasal aspirates were determined using regression 
equations.  Using the serially diluted positive controls, log OD values were plotted 
against the log dilution, generating a regression equation for each plate.  Sample titers 
were calculated by substituting its log OD value into the equation.  Subtraction of the 
mean titers of the negative control plus 2 times the standard deviation from the sample 
titer resulted in a corrected titer.  Only corrected titers were reported.   
Statistical Analysis 
  Data were log transferred (natural log) to stabilize variance terms.  The SAS 
statistical package GLM procedure (SAS Institute Inc.) was used to analyze the data 
through a repeated measures analysis of variance (ANOVA) analyzed as a split-plot 
arrangement of treatments with ‘group’ and ‘calves within group’ as main plot effects 
and ‘day’ and ‘group by day’ as subplot effects.  All comparisons were considered   61
significant at P<0.05.  Where overall tests indicated significance, least squares mean 
pairwise t tests for ‘group by day’ interactions were conducted. 
Results 
Experiment I 
Nasal swabs collected 2 weeks prior to transfection were pooled, while swabs 
collected on days 0, 3, 7, 14, and 21 were collected from each nostril (right and left) 
separately.  DNA extracted from each swab was submitted to Dr. Richard Cooper’s 
Laboratory (Louisiana State University, Baton Rouge, LA) for PCR.  The cecropin B 
gene was not detected by PCR in any calf 2 weeks prior to transfection (Table 3.1).  
Table 3.1.  Experiment I PCR results.  Pre samples taken 2 weeks prior to day 0 were a 
pool from both nostrils.  All other samples were taken from each nostril. 
 
Calf # Treatment Nostril         Day Post Transfection
Pre 0 3 7 14 21
139 E50 R - - + - ++
L ----+
145 E50 R - - ++--
L+ + ---
149 E50 R - ----+
L - ++- +
151 E50 R - + + ---
L+ + ---
146 control R - --+ --
L -----
148 control R - - ++- +
L - + ---
150 control R - - +++-
L - +++-
E50=calves were given 50 µg of plasmid DNA per nostril  
 
Positive PCR results were obtained from both treated calves given 50 µg of plasmid 
DNA per nostril and control calves after transfection.  DNA sequence analysis of PCR 
products from both treated and control calves showed these sequences to be identical to 
the corresponding amplified regions of the cecropin B gene (data not shown).  Positive   62
PCR results were obtained from 2 treated calves at day 0 before these calves received the 
DNA aerosol.  Positive PCR results were obtained from all 4 treated and 2 of 3 control 
calves at day 3.  Cecropin B DNA was detected in all 7 calves at some point during the 
experiment. 
Experiment II 
Total DNA purified from nasal swabs collected on 0, 3, 7, 14, 21, and 28 days 
post transfection/challenge was analyzed by real-time PCR.  This real-time PCR assay 
was designed to amplify a 76-bp region of the cecropin B gene.  For an individual calf the 
relative amount of cecropin B DNA in each sample (days 3, 7, 14, 21, and 28) was 
determined as a ratio compared to day 0 (the calibrator).  The relative amounts of 
cecropin B DNA detected on days 3, 7, 14, 21, and 28 in control calves ranged from 1 to 
34.6 AU, while calves given 25 µg of plasmid DNA per nostril ranged from 1 to 159.8 
AU (Tables 3.2 and 3.3).  For all 4 control calves the amount of cecropin B DNA did not 
appear to increase after day 0, with one exception (Table 3.2).  The amount of cecropin B 
DNA detected for calf #158 at day 3 was 34.6 times higher than at day 0.  Although 
relative amounts of cecropin B DNA that were slightly higher than day 0 were obtained 
from all 4 control calves at some point during the experiment, these levels did not appear 
to be significant.  The amount of cecropin B DNA detected for treated calf #150 at day 3 
was 159.8 times higher than at day 0 (Table 3.3).  Increased amounts of cecropin B DNA 
were also detected in this calf at day 7 and 28.  Calf #157 which was given 25 µg of 
plasmid DNA per nostril had an increased amount of cecropin B DNA detected at day 3.  
However, this level (13.0 AU) is considerably lower than that of treated calf #150 (159.8 
AU).  Two of the 4 treated calves in this experiment had low levels of cecropin B DNA   63
Table 3.2.  Real-time PCR, RT-PCR and isolation data of experiment II control calves.  
Real-time PCR and RT-PCR results are expressed as arbitrary units (AU). 
 
Calf # Sample              Day Post Transfection/Challenge
0 3 7 14 21 28
152
cecropin B DNA 1.0 1.0 1.0 2.8 1.0 1.1
cecropin B mRNA 1.0 1.0 1.0 1.0 1.0 1.0
M. haemolytica
isolation -+----
153
cecropin B DNA 1.0 1.1 1.5 1.0 2.0 1.0
cecropin B mRNA 1.0 1.6 ND 1.0 1.0 1.9
M. haemolytica
isolation --+---
155
cecropin B DNA 1.0 6.4 1.0 1.0 1.0 2.3
cecropin B mRNA 1.0 1.0 1.0 1.0 1.0 1.0
M. haemolytica
isolation -+----
158
cecropin B DNA 1.0 34.6 3.8 6.5 2.0 1.1
cecropin B mRNA 1.0 1.0 1.0 ND 1.0 1.0
M. haemolytica
isolation -++++-
ND= No data; No RNA could be purified  
 
Table 3.3.  Real-time PCR, RT-PCR and isolation data of experiment II calves which 
received 25 µg of plasmid DNA per nostril.  Real-time PCR and RT-PCR results are 
expressed as arbitrary units (AU). 
 
Calf # Sample              Day post transfection/challenge
0 3 7 14 21 28
150
cecropin B DNA 1.0 159.8 18.8 6 4 37.8
cecropin B mRNA 1.0 1.0 1.0 1.0 1.0 1.0
M. haemolytica
isolation -+++- -
157
cecropin B DNA 1.0 13.0 2.3 1.4 2.7 3.4
cecropin B mRNA 1.0 3.9 772.6 2.1 ND 2.8
M. haemolytica
isolation -+-+-+
160
cecropin B DNA 1.0 1.4 1.0 1.0 1.0 2.3
cecropin B mRNA 1.0 1.0 1.0 1.0 1.0 1.0
M. haemolytica
isolation -+++++
161
cecropin B DNA 1.0 1.0 1.0 1.0 1.0 1.2
cecropin B mRNA 1.0 1.0 1.0 1.0 1.0 1.0
M. haemolytica
isolation -++++-
ND= No data; No RNA could be purified  
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comparable with the controls.  Comparisons of cecropin B DNA detected in calves within 
the 2 groups indicated significant (P<0.05) variation among calves in each group.  
Comparisons of cecropin B DNA detected between each group indicated that there was 
not significant (P<0.05) variation between the treated and control groups for the entire 
duration of the experiment nor between each group at a specific day.  Since overall tests 
did not indicate significant variation between control calves and calves given 25 µg of 
plasmid DNA per nostril no further analyses were performed.   
Total RNA purified from nasal aspirates collected on 0, 3, 7, 14, 21, and 28 days 
post transfection/challenge was analyzed by real-time RT-PCR.  This real-time RT-PCR 
assay was designed to amplify a 76-bp region inside the transcribed region of the 
cecropin B gene.  For an individual calf the relative amount of cecropin B mRNA 
expression in each sample (days 3, 7, 14, 21, and 28) was determined as a ratio compared 
to day 0 (the calibrator).  Relative amounts of cecropin B mRNA detected on days 3, 7, 
14, 21 and 28 in control calves ranged from 1 to 1.9 AU, while calves given 25 µg of 
plasmid DNA per nostril ranged from 1 to 772.6 AU (Tables 3.2 and 3.3).  For all 4 
control calves cecropin B mRNA expression did not appear to increase after day 0.  For 
control calf #158 in which increased levels of cecropin B DNA was detected at day 3, no 
increase in mRNA expression was detected at any point of the experiment.  Also, for 
treated calf #150 no increase in mRNA expression was observed.  Increased cecropin B 
mRNA expression was only observed in one treated calf.  The amount of cecropin B 
mRNA expression detected for treated calf #157 at day 7 was 772.6 times higher than at 
day 0.  No increase in mRNA expression was detected in any other calf given 25 µg of 
plasmid DNA at any point of the experiment.  Comparisons of cecropin B mRNA   65
expression in calves within groups indicated variation approaching significance (P<0.05) 
among calves in each group.  Comparisons of cecropin B mRNA expression in each 
group and each group by day indicated that there was no significant (P<0.05) variation 
between groups or between groups by day.  Once again, since overall tests did not 
indicate significant variation between control calves and calves given 25 µg of plasmid 
DNA per nostril no further analyses were performed. 
M. haemolytica 1:A was not isolated from any calf at day 0 (Tables 3.2 and 3.3).  
However, after challenge, M. haemolytica 1:A was isolated from all calves at some point 
during the experiment.  M. haemolytica 1:A was isolated from 3 of 4 control calves at day 
3, but only 2 of 4 calves from days 7 thru 28.  M. haemolytica 1:A was isolated from all 4 
calves given 25µg of DNA per nostril at day 3.  The bacterium was isolated from all 4 of 
these calves at days 7, 14, 21, or 28. 
Serum and nasal aspirate titers for all antibody classes were considerably low 
(Table 3.4).  No differences in serum titers for any class of antibodies were noticed 
between control calves and calves given 25 µg of plasmid DNA per nostril.  Also, no 
differences in nasal aspirate titers for any class of antibodies were noticed between 
control calves and calves given 25 µg of plasmid DNA per nostril with one exception.  
Nasal aspirate IgA titers against whole M. haemolytica 1:A were detected for 2 of 4 
control calves at days 21 and 28, whereas no nasal aspirate IgA titers against whole  
M. haemolytica 1:A were detected for any calf given 25 µg of plasmid DNA per nostril.  
Again, overall tests indicated no significant (P<0.05) differences between the 2 groups or 
between the two groups at any given day post transfection/challenge for any class of 
antibody in either serum or nasal aspirates.   66
Table 3.4.  Mean serum and nasal antibody titers for experiment II calves against whole 
M. haemolytica 1:A antigen. 
 
Sample and antibody class              Day Post Transfection/Challenge
0 3 7 1 42 12 8
Serum
IgG(h &l)
control 0 0 0.9 0.5 0.5 0.4
E25 0 0 1.2 0.8 0.4 0.4
IgG1
control 0 0 0 0.1 0.1 0.1
E25 0 0 0 0.1 0.1 0.1
IgG2
control 0 0 0 0.1 0.1 0.1
E25 0000 0 . 1 0 . 1
IgM
control 0 0 0.2 0.1 0.1 0.1
E25 0 0 0.2 0.1 0.1 0.1
Nasal
  aspirate IgG(h &l)
control 0 0 0 0 0.29 0.16
E25 000000
IgG1
control 0000 0 . 0 1 0
E25 000000
IgG2
control 000000
E25 000000
IgM
control 0 0 0 0.01 0.01 0.01
E25 000 0 . 0 1 00
IgA
control 0 0 0 0 2.58 1.27
E25 000000
E25=calves were given 25 µg of plasmid DNA per nostril
* Overall test indicated significant (P<0.05) differences between groups, least square 
  mean pairwise t tests for group by day interactions were performed
† Significantly (P<0.05) greater than mean titer for controls on that day  
 
    All calves were examined daily for clinical signs of respiratory disease to 
eliminate the possibility of an adventitious infection.  However, no evidence of an 
adventitious infection was observed.   67
Experiment III 
Total DNA purified from nasal swabs collected on 0, 3, 7, 14, 21, and 28 days 
post transfection/challenge was analyzed by real-time PCR as in experiment II.  The 
relative cecropin B DNA level of days 3, 7, 14, 21, and 28 as compared with day 0 of 
control calves ranged from 0 to 4.6 AU, while calves given 50 µg of plasmid DNA per 
nostril ranged from 0 to 988.0 AU (Tables 3.5 and 3.6).  The amount of cecropin B DNA 
detected in calves given 100 µg of plasmid DNA per nostril ranged from 0 to 9983.1 AU 
(Table 3.7).  For all 4 control calves the amount of cecropin B DNA did not appear to   
increase after day 0 (Table 3.5).  For 3 of the 4 calves given 50 µg of plasmid DNA per 
nostril increases in cecropin B DNA were detected (Table 3.6).  For these calves the 
relative amounts of cecropin B DNA ranged from 100.9 to 988.0 AU.  For calves given 
Table 3.5.  Real-time PCR, RT-PCR and isolation data of experiment III control calves.  
Real-time PCR and RT-PCR results are expressed as arbitrary units (AU). 
 
Calf # Sample              Day Post Transfection/Challenge
0 3 7 14 21 28
2189
cecropin B DNA 1.0 1.2 1.6 1.0 1.0 1.0
cecropin B mRNA 1.0 3.2 1.0 1.0 1.0 1.0
M. haemolytica
isolation --+---
2193
cecropin B DNA 1.0 4.6 2.6 4.5 1.0 1.0
cecropin B mRNA 1.0 1.0 1.0 1.0 ND 1.0
M. haemolytica
isolation -+ +---
2237
cecropin B DNA 1.0 2.3 1.0 1.0 1.0 1.0
cecropin B mRNA 1.0 2.4 1.0 1.0 1.0 1.0
M. haemolytica
isolation --+---
2243
cecropin B DNA 1.0 1.0 1.0 1.0 1.0 1.0
cecropin B mRNA 1.0 1.0 1.0 1.0 ND 1.0
M. haemolytica
isolation ------
ND= No data; No RNA could be purified  
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Table 3.6.  Real-time PCR, RT-PCR and isolation data of experiment III calves which 
received 50 µg of plasmid DNA per nostril.  Real-time PCR and RT-PCR results are 
expressed as arbitrary units (AU). 
 
Calf # Sample              Day Post Transfection/Challenge
0 3 7 14 21 28
2013
cecropin B DNA 1.0 1.0 1.0 1.0 1.0 1.0
cecropin B mRNA 1.0 12.1 2.0 1.0 1.0 1.0
M. haemolytica
isolation -+----
2069
cecropin B DNA 1.0 100.9 252.2 2.3 3.4 3.6
cecropin B mRNA 1.0 148.8 6.4 1.0 ND 19.6
M. haemolytica
isolation ------
2091
cecropin B DNA 1.0 469.0 5.3 1.7 1.5 1.0
cecropin B mRNA 1.0 7.9 4.3 1.0 1.0 2.3
M. haemolytica
isolation ---+--
2231
cecropin B DNA 1.0 988.0 1.0 1.0 1.0 1.0
cecropin B mRNA 1.0 209.1 7.9 1.0 1.0 1.0
M. haemolytica
isolation ------
ND= No data; No RNA could be purified  
 
Table 3.7.  Real-time PCR, RT-PCR and isolation data of experiment III calves which 
received 100 µg of plasmid DNA per nostril.  Real-time PCR and RT-PCR results are 
expressed as arbitrary units (AU). 
 
Calf # Sample              Day Post Transfection/Challenge
0 3 7 14 21 28
2012
cecropin B DNA 1.0 2.2 2.1 1.0 1.6 1.0
cecropin B mRNA 1.0 53.1 78.9 1.0 1.0 1.0
M. haemolytica
isolation ------
2027
cecropin B DNA 1.0 1.0 1.0 1.0 1.0 1.0
cecropin B mRNA 1.0 11.0 1.4 1.0 1.0 1.0
M. haemolytica
isolation ------
2077
cecropin B DNA 1.0 9983.1 4.8 5.0 14.2 13.0
cecropin B mRNA 1.0 6.4 5.8 1.0 ND 1.0
M. haemolytica
isolation ------
2178
cecropin B DNA 1.0 1.4 1.1 1.1 1.1 1.0
cecropin B mRNA 1.0 150.7 1.0 2.3 ND 1.2
M. haemolytica
isolation ------
ND= No data; No RNA could be purified    69
100 µg of plasmid DNA per nostril, increases in cecropin B DNA were only detected in 1 
calf (Table 3.7).  At day 3 the relative amount of cecropin B DNA was 9983.1 times 
higher than day 0 in calf #2077.  Comparisons of cecropin B DNA detected in calves 
within the 3 groups indicated significant (P<0.05) variation among calves in each group.  
Comparisons of cecropin B DNA detected between each group indicated that there was 
not any significant (P<0.05) variation between the treated and control groups for the 
entire duration of the experiment or between each group on a specific day.  No further 
analyses were performed because overall tests did not indicate significant variation 
between control calves and the 2 treated groups of calves.   
Total RNA purified from nasal aspirates collected on 0, 3, 7, 14, 21, and 28 days 
post transfection/challenge was analyzed by real-time RT-PCR as in experiment II.  For 
all 4 control calves no increase in cecropin B mRNA expression after day 0 was observed 
(Table 3.5).  Increases in cecropin B mRNA were observed at day 3 in 2 of the 4 calves 
given 50 µg of plasmid DNA per nostril (Table 3.6).  Likewise, increases in cecropin B 
mRNA were observed at day 3 in 2 of the 4 calves given 100 µg of plasmid DNA per 
nostril as well (Table 3.7).  Comparisons of cecropin B mRNA expression among calves 
within the three groups indicated no significance (P<0.05) in variation.  However, 
comparisons of mean cecropin B mRNA expression between groups and betweens 
groups by day indicated that there was significant (P<0.05) variation between the 3 
groups.  When compared to the control group cecropin B mRNA expression was 
significantly (P<0.05) increased in both treated groups at 3 and 7 days post 
transfection/challenge (Table 3.8).  Analyses were based on least squares means of the 
natural log-transformed data, although raw data means were reported.   70
Table 3.8.  Mean cecropin B mRNA (arbitrary units) detected in calves from experiment 
III.  Asterisks indicate significant (P<0.05) differences as determined by least squares 
means pairwise t test for group by day interactions.  Raw means are reported.   
 
Day Controls E50 E100
0 1.0 1.0 1.0
3 1.9 94.5* 55.3*
7 1.0 5.2* 21.8*
14 1.0 1.0 1.3
21 1.0 1.0 1.0
28 1.0 6.0 1.1
E50=calves were given 50 µg of plasmid DNA per nostril
E100=calves were given 100 µg of plasmid DNA per nostril  
ELISA was used to detect cecropin B in nasal aspirates collected on 0, 3, 7, 14, 
21, and 28 days post transfection/challenge.  Cecropin B was detected in all calves at day 
0 (Figure 3.1).  A significant (P<0.05) increase in the mean amount of cecropin B 
detected in the 2 groups of calves given 50 µg or 100 µg of plasmid DNA per nostril was 
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E50=calves were given 50 µg of plasmid DNA per nostril
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* Significantly (P<0.05) greater than mean cecropin B
   detected for controls at that day  
 
Figure 3.1.  Mean cecropin B peptide detection by ELISA.  Results are expressed in 
ng/ml amounts. 
 
observed between days 7 and 14.  Furthermore, mean cecropin B detected in calves given 
50 µg or 100 µg of plasmid DNA per nostril was significantly (P<0.05) greater than 
mean amounts detected in the control calves at day 14.  Mean amounts of peptide 
detected in these 2 treated groups at day 14 were not significantly different (P<0.05) from   71
each other, although slightly higher amounts of cecropin B were detected in calves given 
50 µg of plasmid DNA per nostril.  For all calves cecropin B detection dropped at days 
21 and 28.  This decrease in peptide was only statistically significant (P<0.05) for the 2 
treated groups.   
M. haemolytica 1:A was not isolated from any calf at day 0 (Tables 3.5, 3.6, and 
3.7).  However, after challenge M. haemolytica 1:A was isolated from 3 of 4 control 
calves at some point during the experiment (Table 3.5).  At day 3 M. haemolytica 1:A 
was isolated from only 1 of 4 (by enrichment media) calves given 50 µg of plasmid DNA 
per nostril, and from only one other calf in this group on day 14 (Table 3.6).  M. 
haemolytica 1:A was not isolated from any of the 4 calves given 100 µg of plasmid DNA 
per nostril at any point of the experiment (Table 3.7). 
Serum and nasal aspirate titers for all antibody classes were considerably higher 
than those of the experiment II calves (Table 3.9).  Serum titers for all classes of antibody 
and all 3 groups peaked at day 21.  Serum antibody titers for all classes against whole M. 
haemolytica 1:A were higher for calves given 50 µg of plasmid DNA per nostril than 
control calves and calves given 100 µg of plasmid DNA per nostril.  No differences in 
serum titers for any class of antibody were noticed between control calves and calves 
given 100 µg of plasmid DNA per nostril with one exception.  Serum IgG1 titers against 
whole M. haemolytica 1:A were slightly higher for calves given 100 µg of plasmid DNA  
per nostril than titers for control calves.  The nasal aspirate IgG (h & l), IgG1, IgG2, and 
IgM titers against whole M. haemolytica 1:A for the 3 groups were relatively equal.  The 
nasal aspirate IgA titers for control calves appeared to be higher than calves given 50 µg 
or 100 µg of plasmid DNA per nostril.  The nasal aspirate IgA titers against whole   72
Table 3.9.  Mean serum and nasal antibody titers for experiment III calves against whole 
M. haemolytica 1:A antigen. 
 
Sample and antibody class              Day Post Transfection/Challenge
0 3 7 14 21 28
Serum
IgG(h &l)*
control 0.1 0.1 18.1 41.1 47.4 47.8
E50 0.1 0.1 84.1
† 118.5
† 135.1
† 122.4
†
E100 0.1 0.1 14.9 49.9 74.2 56.3
IgG1*
control 0.1 0.1 8.8 16.4 25 23.3
E50 00 24.4
† 41.8
† 63.5
† 51.3
†
E100 0 0 8.7 26.1 32.6 25.4
IgG2
control 0 0 1 3.4 9.6 6.2
E50 0 0 2.8 6.3 14.7 11.6
E100 0 00 . 1 2 . 696 . 3
IgM
control 000000
E50 000000
E100 000000
Nasal
  aspirate IgG(h &l)
control 0.13 0.06 0.03 0.02 0.61 0.36
E50 0.02 0 0.18 0.04 0.71 0.53
E100 0.36 0 0.02 0.02 0.38 0.21
IgG1
control 0.01 0.01 0.01 0.01 0.01 0.01
E50 0 0 0.02 0.01 0.01 0.03
E100 0 0 0.01 0.01 0.01 0.01
IgG2
control 0.01 0.01 0 0 0.01 0.01
E50 0 0.01 0 0 0 0.01
E100 000000
IgM
control 0 0 0.01 0.01 0.01 0.01
E50 0 0 0.01 0 0.01 0.01
E100 0 0 0.01 0 0.01 0.01
IgA
control 0.99 1.16 1.21 0.47 5.62 3.15
E50 0.03 0 0.67 0.46 3.28 0.12
E100 1.17 0 0 0 0.84 0.36
E50=calves were given 50 µg of plasmid DNA per nostril
E100=calves were given 100 µg of plasmid DNA per nostril
* Overall test indicated significant (P<0.05) differences between groups, least square 
  mean pairwise t tests for group by day interactions were performed
† Significantly (P<0.05) greater than mean titer for controls on that day  
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M. haemolytica 1:A for calves given 50 µg of plasmid DNA per nostril were also slightly 
higher than calves given 100 µg of DNA per nostril.  
Overall tests indicated no significant (P<0.05) differences between each group or 
between each group at any given day for any class of antibody in nasal aspirates, but only 
for IgG2 and IgM titers in serum.  Tests indicated that there was significant (P<0.05) 
variation between groups by day, while variation between groups for the entire 
experiment were approaching significance.  Least squares means pairwise t test for group 
by day interactions indicated that mean serum IgG (h & l) and IgG1 titers for calves given 
50 µg of plasmid DNA per nostril were significantly (P<0.05) greater than mean titers for 
the control group and the group of calves given 100 µg of plasmid DNA per nostril at 7 
thru 28 days post transfection/challenge (Table 3.9).  Mean serum IgG (h & l) and IgG1 
titers for calves given 100 µg of plasmid DNA per nostril were not significantly (P<0.05) 
different than mean titers for the control group at any point of the experiment. 
All calves were examined daily for clinical signs of respiratory disease to 
eliminate the possibility of an adventitious infection.  Again, no evidence of an 
adventitious infection was observed. 
Discussion 
  Previous studies have demonstrated the possible use of antibacterial peptides such 
as cecropin B as topical or injectable antibiotics against pathogens otherwise resistant to 
conventional antibiotics (Hancock et al., 1998).  However, cost of production may limit 
this peptide’s usefulness.  The most cost efficient peptide synthesis methods employed at 
the present time are still unreasonably expensive (Hancock et al., 1998).  One possible 
cost-effective approach would be to transfer the cecropin B gene into the species of   74
interest, and let the recipient’s biosynthesis mechanisms synthesize the peptide.  Most 
gene transfer studies involving the cecropin B gene or genes of cecropin B homologues 
and analogues have been performed in plants and fish, but also in mice and oysters 
(Buchanan et al., 2001, Chiou et al., 2002, Dunham et al., 2002, Hagius et al., 1996, 
Hancock et al., 1998, Sarmasik et al., 2002, Zhang et al., 1998).  These studies have met 
with some success.  Most show that cecropin B can be expressed at the RNA and protein 
level, while displaying some bacterial resistance.  
  Results of experiment I indicate that the cecropin B gene can be detected in DNA 
extracted from nasal swabs collected from transfected calves.  Furthermore, the cecropin 
B gene could be detected for at least 3 weeks post transfection.  From this data it seems 
obvious that aerosolization using the previously described methods was successful in 
depositing the gene into the nasal passage of calves.     
  Detection of the cecropin B gene at day 0 prior to these calves being transfected 
and in untreated control calves could implicate the possible presence of a native bovine 
cecropin or cecropin-like gene.  However, transmission of the gene can not be ruled out.  
Indeed, studies suggest that cecropins may be widespread throughout the animal kingdom 
(Boman et al., 1991, Hancock et al., 1998, Marshall and Arenas, 2003).  A cecropin was 
found in the upper part of the porcine small intestine (Lee et al., 1989).  Cecropins 
contribute to the animal’s innate immunity in every species in which they have been 
found.  As of this study no bovine cecropin has been identified.  Many other 
antimicrobial peptides have been found in cattle including cathelicidins, lactoferricins, 
and the β-defensin, Tracheal Antimicrobial Peptide (TAP), among others (Diamond et al., 
2000, Haukland et al., 2001, Huttner et al., 1998b).  Most of these peptides are very   75
different from cecropins; for example TAP and the cathelicidins contain several cysteine 
residues which form disulfide bonds.  Cecropins are cysteine-free peptides.   
  It is also possible that the cecropin B gene was transmitted from treated to control 
calves.  No cecropin B DNA was detected in any experiment I calf two weeks prior to 
transfection.  Also, no cecropin B DNA was detected in the 3 control calves on day 0.  
Swabs were collected from these calves before any aerosolization of plasmid DNA, then 
the calves were allowed to return to pasture.  The 4 treated calves were sampled, then 
immediately aerosolized with plasmid DNA one at a time with the remaining calves in 
the chute right behind them.  It could be possible that some of the plasmid DNA 
aerosolized escaped into the air and contaminated subsequent calves.  Unfortunately no 
records were kept as to the order in which calves were sampled and transfected.  
Following transfection all treated calves were allowed to return to pasture with the 
controls where transmission could have occurred.  To reduce the possibility of 
transmission, groups in experiments II and III remained isolated from each other.  
Furthermore, all calves were sampled before aerosolization of plasmid DNA, and treated 
calves were aerosolized alone in the chute.  Researchers wore protective equipment.   
  The real-time PCR and RT-PCR assays were designed to quantify cecropin B 
DNA and mRNA detected.  The primers and fluorescent dye-labeled probe were 
designed to amplify a specific 76-bp region of the cecropin B gene.  This sequence is 
inside the transcribed region of the gene.  Without a pure control containing a known 
number of cecropin B gene copies, absolute quantitations could not be performed.  
Relative quantitations are easy to perform because quantity is expressed relative to some 
basis sample (i.e. the calibrator).  Quantity is determined from the standard curve and   76
then divided by the quantity of the calibrator.  Here, quantitation was based on 5-fold 
serial dilutions of bovine DNA spiked with the cecropin B gene.    For an individual calf 
the relative quantitation at days 3, 7, 14, 21, and 28 was determined as a ratio compared 
to day 0.  Day 0 results were designated as the calibrator for each calf.  Each calf’s day 0 
quantity was arbitrarily chosen as its calibrator because it would be expected to have the 
lowest expression level of the target.  The day 0 quantities became the 1x sample, 
therefore arbitrary units (AU) can be read as an n-fold increase in either cecropin B DNA 
or cecropin B mRNA expression.  Hence, 3.0 AU of cecropin B mRNA at day 3 would 
indicate that cecropin B mRNA expression was 3.0 times higher than at day 0.  While 
300.0 AU of mRNA at day 3 would indicate that cecropin B mRNA expression was 
300.0 times higher than at day 0.   
  The measurement of cecropin B DNA following transfection provided an 
indication of the longevity of the gene.  Following transfection the plasmid was either 
cleared from the mucosa or delivered to cells where the gene was stably inserted into the 
genome.  In both experiments II and III the cecropin B gene could be detected even at 28 
days post transfection. In most cases these DNA levels were comparable with the levels 
detected in controls.  Once again the detection of cecropin B DNA in untreated calves 
could be due to a native bovine cecropin, therefore it is unclear whether or not levels of 
cecropin B DNA detected in transfected calves at 4 weeks is a persistence of the 
transferred gene.  Further research may be necessary to determine the longevity of 
transfection.  
  In all 3 treated groups of calves there was significant variation in the amounts of 
cecropin B DNA detected, but no significant differences were observed between treated   77
groups and their respective control groups.  Although increased amounts of cecropin B 
DNA were detected in some individual calves from each of the 3 treated groups, the data 
appeared to be statistically insignificant.  However, levels of cecropin B DNA detected in 
those treated calves was noticeably higher than any control calf indicating some 
difference between control and treated calves.  Perhaps using larger numbers of test 
calves would validate these findings.  
  Results of experiment II indicate that an aerosol of 25 µg of plasmid DNA per 
nostril was not enough to consistently transfect calves.  An increase in cecropin B mRNA 
expression was detected in only one calf given 25 µg of plasmid DNA per nostril.  
Whereas this level of expression was higher than any of the experiment III treated calves, 
this result appeared to be statistically insignificant.  Furthermore, M. haemolytica 1:A 
was isolated more frequently from calves given 25 µg of plasmid DNA per nostril than 
any other group in experiments II or III.  Even if increased mRNA expression went 
undetected in these calves it did not provide protection against M. haemolytica 1:A 
following challenge.   
  Results of experiment III mean cecropin B mRNA expression comparisons 
between the treated and control groups indicated that significant differences existed 
between the 3 groups.  When compared to the control group cecropin B mRNA 
expression was significantly increased in calves given 50 µg or 100 µg of plasmid DNA 
per nostril at 3 and 7 days post transfection.  The highest levels of cecropin B mRNA 
were achieved in most calves at day 3, and expression appeared to decline in these calves 
between days 3 and 7.  Analyses were based on least squared means of the natural log-
transformed data, although raw data means were reported.     78
ELISA was then used to detect cecropin B peptide in nasal aspirates collected 
from experiment III calves.  Cecropin B was detected in all calves at day 0.  Once again 
this implies the presence of native bovine cecropin.  However, a significant increase in 
the mean amount of cecropin B detected in the 2 groups of calves given 50 µg or 100 µg 
of plasmid DNA per nostril was observed at day 14, while no such increase was observed 
in the control calves.  Mean amounts of the peptide detected in these 2 treated groups at 
day 14 were not significantly different from each other, although slightly higher amounts 
of cecropin B were detected in calves given 50 µg of plasmid DNA per nostril.  For all 
calves in experiment III, cecropin B peptide detection dropped at days 21 and 28.  These 
suspicious ELISA results were repeated and validated.   
Evidence has shown that the cecropin B activity is dependent on the concentration 
of cecropin (Boman et al., 1991).  Binding sufficient amounts of cecropin to form a 
monolayer is necessary to modify the bacterial membranes (Steiner et al., 1988).  
Bacteria which are resistant to cecropin still bind large amounts in a non-productive 
manner, indicating that cecropins act stoichiometrically.  The activity of cecropin B is a 
matter of mass action, and is not catalytic in nature (Steiner et al., 1988).  Hence, more 
peptide is required to kill more bacteria.  If mRNA and subsequent peptide production 
was halted, then a decline in available cecropin B peptide would occur.  The drastic 
decline in cecropin B detection at days 21 and 28 is likely a result of all available peptide 
being sequestered to kill bacteria, while no more peptide was being produced.   
The raw data showed that expression of cecropin B at the mRNA and protein 
level appeared to be more consistent among calves given 50 µg of plasmid DNA per 
nostril than among calves given 100 µg of plasmid DNA per nostril.  Certainly mean   79
cecropin B mRNA and peptide expression levels were higher in calves given 50 µg of 
plasmid DNA per nostril.  However these levels were not found to be significantly 
different from calves given 100 µg of plasmid DNA per nostril.  Protection against 
challenge with a virulent stain of M. haemolytica 1:A seemed more apparent in calves 
given 100 µg of plasmid DNA per nostril where M. haemolytica 1:A was not isolated 
from any calf at any point during the experiment.  M. haemolytica 1:A was isolated from 
2 of the 4 calves given 50 µg of plasmid DNA per nostril.  It should be noted that M. 
haemolytica 1:A was not isolated from the 2 calves given 50 µg of plasmid DNA per 
nostril in which the highest levels of cecropin B mRNA and peptide expression were 
detected.   
Further differences between the 3 groups of experiment III can be seen in serum 
and nasal aspirate antibody titers against whole M. haemolytica 1:A antigen.  Serum IgG 
(h & l), IgG1, and IgG2 titers were consistently higher in calves given 50 µg of plasmid 
DNA per nostril, while these titers detected in control calves and calves given 100 µg of 
plasmid DNA per nostril did not appear to differ.  In contrast higher IgA antibody titers 
in nasal aspirates were achieved in control calves.  This trend was also observed in 
experiment II where IgA titers were higher in control calves than calves which received 
25 µg of plasmid DNA per nostril.  In neither experiment were these IgA titers shown to 
be statistically significant, nevertheless the trend was observed.  It would appear that in 
the absence of peptide, M. haemolytica 1:A antigens were more readily available for IgA 
production.  No sound explanation for consistently higher serum IgG (h & l), IgG1, and 
IgG2 antibody titers in calves given 50 µg of plasmid DNA per nostril can be offered.  
However, mean cecropin B mRNA and peptide expression levels were highest in calves   80
given 50 µg of plasmid DNA per nostril.  Perhaps in these calves inhibition of M. 
haemolytica 1:A eased phagocytosis and enhanced antibody production.  However this 
would not explain why titers detected in control calves and calves given 100 µg of 
plasmid DNA per nostril did not appear to differ. 
Antibody titers against whole M. haemolytica 1:A antigen at day 0 (before 
challenge) were likely the result of prior exposure to M. haemolytica 1:A.  These findings 
were consistent with the results of a previous study (Brennan et al., 1998).  These titers 
were not believed to affect the data collected since they were measured to detect 
differences in antibody production between control and treated groups, not to determine 
the efficacy of treatments on antibody production.  
Very few studies are available describing transfected mammals expressing 
cecropin B or cecropin B-like peptides.  In a preliminary report researchers using a 
cecropin B analog to transfect mice found the mice to be resistant to Brucella abortus, a 
bovine pathogen (Hagius et al., 1996).  There are many indications that a transgenic or 
gene therapeutic approach may be useful in enhancing bacterial resistance in food 
animals, thereby reducing the use of conventional antibiotics.  Results of this study show 
that calves transfected with sufficient copies of the cecropin B gene can express cecropin 
B at the RNA and protein level, while displaying some resistance to M. haemolytica 1:A.   81
CHAPTER 4 
 
CHANGES IN THE NORMAL AND TRANSIENT NASAL FLORA OF CALVES 
TRANSFECTED WITH A GENE CODING FOR CECROPIN B 
 
 
Introduction 
Although Pasteurella multocida and Haemophilus somnus have been associated 
with Bovine Respiratory Disease (BRD), the major etiologic agent of bovine pneumonic 
pasteurellosis is Mannheimia haemolytica 1:A (Dalgleish, 1990, Frank, 1986).  M. 
haemolytica serotype 1, biotype A (formally known as Pasteurella haemolytica 1:A) is a 
nonmotile, Gram-negative coccobacilli or rod, and a facultative anaerobe.  M. 
haemolytica 1:A is considered to be part of the transient bacterial flora in the upper 
respiratory tract (URT) of clinically healthy cattle, and can exist in the nasal cavity in 
very low numbers (Carter et al., 1991, Whiteley et al., 1992).       
In addition to M. haemolytica, Pasteurella Multocida, and Haemophilus somnus, 
the bacteria commonly associated with BRD, the nasal passage of cattle is home to a 
diverse collection of bacteria that make up the normal and transient flora.  Although a 
complete listing of all the bacteria found in the nasal passage of cattle does not appear to 
have been reviewed recently, there are some organisms mentioned in the literature.  Some 
prominent bacteria found in the URT include Gram-positive bacteria such as 
Micrococcus, Corynebacterium, Staphylococcus, Streptococcus, and Bacillus as well as 
Gram-negative bacteria such as Pseudomonas, Actinobacter, Moraxella, Neisseria 
catarrhalis, and Escherichia coli (Corbeil et al., 1985, Woldehiwet et al., 1990).  Other 
members of the bovine nasal flora may include Gram-positive bacteria such as 
Lactobacillus, Streptomyces, and Diplococcus pneumoniae as well as Gram-negative   82
bacteria such as Chromobacterium, Achromobacter, Serratia, Flavobacterium, Proteus, 
and Klebsiella (Magwood et al., 1969).  These species of bacteria have been found to 
start colonizing the URT as early as the calf’s first day of life (Woldehiwet et al., 1990).  
The total bacterial load in the nasal passage increases with age, and is influenced by 
environmental temperature (Woldehiwet et al., 1990).  The purpose of this study was to 
ascertain whether or not transfecting the URT of cattle with a gene coding for cecropin B 
would result in a change in the indigenous and transient flora. 
Materials and Methods 
Nasal aspirates collected from experiment II and III calves on 0, 3, 7, 14, 21, and 
28 days post challenge (DPC) were analyzed by bacterial culture.   Aliquots of these 
samples were diluted in sterile duPBS to 1:10, 1:100, and 1:1000 of the original 
concentration.  Within one to four hours after collection, small amounts (0.1 ml) of each 
dilution and of the undiluted sample were directly plated onto separate 1% yeast blood 
agar plates (YBP) (Difco, Becton, Dickinson and Co., Sparks, MD.).  The plates were 
allowed to incubate in a 5% CO2 atmosphere for up to 72 hours at 37
oC.  The plates were 
observed for bacterial growth every 24 hours.  Isolated colonies of M. haemolytica 1:A as 
well as the calves’ bacterial flora were counted, identified, and recorded. 
Small amounts (0.1 ml) of the undiluted sample were inoculated into Difco 
thioglycollate enrichment medium (Becton, Dickinson and Co., Sparks, MD.) plus 0.1% 
horse serum.  The thioglycollate tubes were allowed to incubate for up to 72 hours at 
37
oC.  The tubes were observed for bacterial growth every 24 hours.  Observed growth 
was then recorded and streaked onto 1% YBP, which were incubated in a 5% CO2   83
atmosphere for 24 hours at 37
oC.  Isolated colonies of M. haemolytica 1:A as well as the 
calves’ bacterial flora were identified and recorded. 
Pure cultures for representative colonies of all macroscopically different types 
were first identified on the basis of colonial morphology.  These representative colonies 
were then streaked onto manitol salt and McConkey agar plates as well as triple sugar 
iron (TSI), citrate, and urea slants (Difco, Becton, Dickinson and Co., Sparks, MD.).  
Smears of these representative colonies were also Gram (Difco, Becton, Dickinson and 
Co., Sparks, MD.) stained.  Bacteria were identified on the basis of morphological, 
cultural, and biochemical characteristics of the isolates in pure culture.  Coccus shaped 
bacteria were further identified by catalase (H2O2) test.  Suspected M. haemolytica 1:A 
colonies were further identified by the presence of  hemolysis, as well as an agglutination 
and oxidase (Difco, Becton, Dickinson and Co., Sparks, MD.) test.  All findings were 
recorded. 
Results 
During the summer months of experiment II, M. haemolytica 1:A was not isolated 
from any calf at day 0 (Tables 4.1 and 4.2).  However, after challenge M. haemolytica 
1:A was isolated from all calves at some point during the experiment.  M. haemolytica 
1:A was isolated from 3 of 4 control calves at day 3, but only 2 of 4 calves from days 7 
thru 28.  M. haemolytica 1:A was isolated from all 4 calves given 25 µg of plasmid DNA 
per nostril at day 3.  M. haemolytica 1:A was also isolated from all 4 of these calves at 
either days 7, 14, 21, or 28.  
During the fall months of experiment III, M. haemolytica 1:A was not isolated 
from any calf at day 0 (Tables 4.3-4.5).  However, after challenge M. haemolytica 1:A    84
Table 4.1.  Summary of bacteria (CFU) isolated on direct media from experiment II control calves. 
                                            CALF #    
DAY  158  153 155 152 
0 2.5x10
5 Micrococcus spp.  7000 Corynebacterium spp.  6x10
4 Achromobacter spp.  6x10
4 Corynebacterium spp. 
   400  Micrococcus spp.  >1x10
4 Micrococcus spp.   
              
3  2.5x10
5 Mannheimia   2750 Corynebacterium spp.  1.9x10
4 M. haemolytica 7x10
4 M. haemolytica* 
                    haemolytica*  100 Bacillus spp.  300 Micrococcus spp.  1.1x10
5 Micrococcus spp. 
       2000  Streptococcus spp. 
              
7 3.1x10
4 Corynebacterium spp.  1000 Gram (-) coccus**  1050 Corynebacterium spp.  No isolations 
  2.1x10
5 M. haemolytica 1250  M. haemolytica  100 Staphylococcus spp.   
              
14 100  Bacillus spp.  1000 Bacillus spp.  No isolations  No isolations  
 100  Escherichia spp.  1000 Escherichia spp.     
  3000 M. haemolytica*  1x10
4 Micrococcus spp.     
 100  Micrococcus spp.  4500 Streptococcus spp.     
              
21 300  Bacillus spp.  4000 Corynebacterium spp.  1000 Bacillus spp.  600 Bacillus spp. 
  3.5x10
4 M. haemolytica  3650 Streptococcus spp.  400 Corynebacterium spp.  2x10
4 Escherichia coli 
 5500  Streptococcus spp.  5x10
4 Streptomyces spp.  100 Escherichia spp.  7133 Streptococcus spp. 
              
28 7000  Achromobacter spp.  1x10
4 Corynebacterium spp.  100 Achromobacter spp.  300 Bacillus spp. 
 200  Micrococcus spp.   300  Micrococcus spp.  800 Micrococcus spp. 
              
*Also isolated from enrichment media 
**Unable to identify 
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Table 4.2.  Summary of bacteria (CFU) isolated on direct media from experiment II calves that were given 25 µg of plasmid DNA per 
nostril. 
 
                                            CALF #    
DAY  150  157 160 161 
0 4.3x10
5 Acinetobacter spp.  2.8x10
6 Pseudomonas spp.  1x10
6 Micrococcus spp.  1.2x10
5 Corynebacterium spp. 
     1x10
5 Pseudomonas spp.  >1x10
6 Pseudomonas spp. 
              
3 1000  Corynebacterium spp.  5.8x10
4 M. haemolytica* 1.6x10
4 M. haemolytica* 1.6x10
4 M. haemolytica 
  1x10
5 Mannheimia     3200 Micrococcus spp. 
                    haemolytica    100  Staphylococcus spp. 
 2000  Micrococcus  spp.     
              
7 2.1x10
4 Corynebacterium spp.  3x10
4 Achromobacter spp.  4000 M. haemolytica  4x10
4 Escherichia coli 
 4x10
5 Escherichia spp.  1000 Corynebacterium spp.    2.9x10
5 M. haemolytica 
  2.8x10
5 M. haemolytica  2.3x10
4 Lactobacillus spp.     
    1.2x10
4 Staphylococcus spp.   
14 3000  Achromobacter spp.  6x10
4 M. haemolytica*  200 Bacillus spp.  1.4x10
4 Corynebacterium spp. 
 1x10
4 Gram (-) coccus**  100 Micrococcus spp.  3.4x10
4 M. haemolytica 5x10
4 M. haemolytica 
  400 M. haemolytica*   2x10
4 Micrococcus spp.  2x10
4 Micrococcus spp. 
 5500  Streptococcus spp.    6x10
4 Streptococcus spp.   
              
21 4x10
4 Achromobacter spp.  4000 Alcaligenes spp.  1.6x10
4 Bacillus spp.  550 Bacillus Spp. 
 1000  Bacillus spp.  4750 Escherichia spp.  6x10
4 Corynebacterium spp.  9.4x10
4 Corynebacterium spp. 
 7500  Escherichia spp.  200 Micrococcus spp.  6000 E. coli   100 E. coli  
     1.7x10
4 M. haemolytica 1x10
4 M. haemolytica* 
              
28 3.2x10
5 Achromobacter spp.  3x10
4 M. haemolytica  2x10
4 Achromobacter spp.  2.6x10
5 Corynebacterium spp. 
 650  Micrococcus spp.    1200 M. haemolytica*  1050 Micrococcus spp. 
*Also isolated from enrichment media 
**Unable to identify   86
Table 4.3.  Summary of bacteria (CFU) isolated on direct media from experiment III control calves. 
 
                                            CALF #    
DAY  2193  2189 2237 2243 
0 500  Corynebacterium spp.  4x10
4 Corynebacterium spp.  750 Corynebacterium spp.  6.8x10
4 Corynebacterium spp. 
 100  Bacillus spp.  1750 Bacillus spp.  400 Bacillus spp.  400 Bacillus Spp. 
 300  Micrococcus spp.  4.3x10
4 Micrococcus spp.     
              
3 650  Corynebacterium spp.  2750 Achromobacter spp.  2.4x10
5 Corynebacterium spp.  4.6x10
4 Corynebacterium spp. 
  5000 Mannheimia    1700 Bacillus spp.  200 Streptococcus spp. 
                    haemolytica   2200  Escherichia spp.   
 100  Streptococcus  spp.     
              
7 650  Achromobacter spp.  200 Achromobacter spp.  3x10
4 Achromobacter spp.  5x10
4 Corynebacterium spp. 
 650  Corynebacterium spp.  600 Corynebacterium spp.  1.2x10
5 Corynebacterium spp.  200 Micrococcus spp. 
  1000 M. haemolytica 2850  M. haemolytica 6.5x10
4 M. haemolytica  300 Streptococcus spp. 
     600 Micrococcus spp.   
              
14 400  Corynebacterium spp.  1200 Streptomyces spp.  1.6x10
4 Corynebacterium spp.  900 Streptomyces spp. 
 700  Micrococcus spp.    2000 Bacillus spp.   
     1000
 Micrococcus spp.   
              
21 5200  Micrococcus spp.  1.3x10
5 Micrococcus spp.  1.1x10
5 Corynebacterium spp.  8000 Corynebacterium spp. 
     1900  Micrococcus spp.  5300 Micrococcus spp. 
              
28 5.5x10
4 Corynebacterium spp.  600 Coliform spp.*  1.2x10
5 Corynebacterium spp.  7.8x10
4 Corynebacterium spp. 
 1100  Staphylococcus spp.  1.1x10
5 Corynebacterium spp.  3350 Micrococcus spp.  1.1x10
5 Micrococcus spp. 
   100  Bacillus spp.     
   3x10
4 Micrococcus spp.     
              
*Unable to identify   87
Table 4.4.  Summary of bacteria (CFU) isolated on direct media from experiment III calves that were given 50 µg of plasmid DNA 
per nostril. 
 
                                            CALF #    
DAY  2231 2013 2091 2069 
0 1.7x10
4 Corynebacterium pp.  5.5x10
4 Corynebacterium spp.  3100 Corynebacterium spp.  300 Corynebacterium spp. 
 200  Bacillus spp.  6500
 Micrococcus spp.  300 Bacillus spp.  400 Bacillus spp. 
 1.2x10
4 Micrococcus spp.    2500
 Micrococcus spp.  300
 Micrococcus spp. 
              
3 500  Achromobacter spp.  2000 Achromobacter spp.  100 Corynebacterium spp.  500 Achromobacter spp. 
 3.7x10
4 Corynebacterium spp.  1950 Corynebacterium spp.  5350
 Micrococcus spp.  100 Bacillus spp. 
 100  Bacillus spp.  400 Streptococcus spp.  100 Streptococcus spp.  2000
 Micrococcus spp. 
   Mannheimia haemolytica*   400  Streptococcus spp. 
              
7 1.7x10
4 Achromobacter spp.  1.6x10
4 Corynebacterium spp.  5.7x10
4 Corynebacterium spp.  2500 Achromobacter spp. 
 5300  Corynebacterium spp.  100 Micrococcus spp.    1100 Corynebacterium spp. 
 200  Streptococcus spp.     
              
14 9500  Corynebacterium spp.  3.1x10
5 Corynebacterium spp.  5366 Corynebacterium spp.  2.4x10
4 Corynebacterium spp. 
 550  Micrococcus spp.  300 Micrococcus spp.  4050 Bacillus spp.  100 Bacillus spp. 
      4x10
4 M. haemolytica**   
              
21 2.2x10
4 Corynebacterium spp.  7.1x10
4 Corynebacterium spp.  5500 Corynebacterium spp.  2600 Corynebacterium spp. 
 100  Micrococcus spp.  200 Micrococcus spp.    100 Bacillus spp. 
              
28 4.3x10
4 Corynebacterium spp.  5.3x10
4 Corynebacterium spp.  2200 Corynebacterium spp.  5.2x10
4 Corynebacterium spp. 
     4x10
4 Micrococcus spp.  100 Bacillus spp. 
      300  Micrococcus spp. 
              
*Isolated from enrichment media, but not direct; no colony count 
**Also isolated from enrichment media   88
Table 4.5.  Summary of bacteria (CFU) isolated on direct media from experiment III calves that were given 100 µg of plasmid DNA 
per nostril. 
 
                                            CALF #    
DAY  2027  2178 2077 2012 
0 1200  Corynebacterium spp.  1.6x10
5 Achromobacter spp.  8.5x10
4 Corynebacterium spp.  1000 Corynebacterium spp. 
 200  Bacillus spp.  2x10
4 Micrococcus spp.  2200 Escherichia spp.  500
 Micrococcus spp. 
     4.5x10
4 Micrococcus spp.   
              
3 600  Achromobacter spp.  700 Corynebacterium spp.  400 Achromobacter spp.  2950 Achromobacter spp. 
 2x10
4 Corynebacterium spp.  300
 Micrococcus spp.  100 Corynebacterium spp.  1550 Corynebacterium spp. 
     2x10
4 Micrococcus spp.  100 Bacillus spp. 
              
7 6.5x10
4 Corynebacterium spp.  8400 Corynebacterium spp.  4000 Achromobacter spp.  1x10
4 Corynebacterium spp. 
 300
 Micrococcus Spp.  1000 Micrococcus spp.  6750 Corynebacterium spp.  100 Bacillus spp. 
   100  Streptococcus spp.  100 Streptococcus spp.  100 Micrococcus spp. 
      100  Streptococcus spp. 
              
14 5000  Corynebacterium spp.  600 Corynebacterium spp.  300 Micrococcus spp.  5x10
5 Corynebacterium spp. 
 650  Micrococcus spp.  100 Micrococcus spp.    1.4x10
4 Micrococcus spp. 
 3x10
4 Pseudomonas spp.       
              
21 3.8x10
5 Corynebacterium spp.  1050 Corynebacterium spp.  7050 Corynebacterium spp.  1.7x10
5 Corynebacterium spp. 
 100  Bacillus spp.  100 Bacillus spp.  100 Bacillus spp.  100 Bacillus spp. 
   600  Micrococcus spp.    2400 Micrococcus spp. 
              
28 2.6x10
5 Corynebacterium spp.  8x10
5 Corynebacterium spp.  1000 Corynebacterium spp.  3x10
5 Corynebacterium spp. 
 1x10
4 Bacillus spp.    900 Bacillus spp.  100 Bacillus spp. 
 1400  Micrococcus spp.    4x10
5 Micrococcus spp.  800 Micrococcus spp. 
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was isolated from 3 of 4 control calves at some point during the experiment.  M. 
haemolytica 1:A was isolated from only 1 of 4 (by enrichment media) calves given 50 µg 
of plasmid DNA per nostril at day 3, and only 1 of 4 calves from days 7 thru 28.  M. 
haemolytica 1:A was not isolated from any of the 4 calves given 100 µg of plasmid DNA 
per nostril at any point in the experiment.   
After challenge M. haemolytica 1:A was isolated a total of 38 times from all five 
groups.  The organism was isolated 28 times on direct media and 10 times in enrichment 
media.  Many times it was isolated on both direct and enrichment media, only once was it 
isolated solely in enrichment media.  M. haemolytica 1:A was isolated with a 29% 
frequency from experiment II control calves and a 63% frequency from calves given 25 
µg of plasmid DNA per nostril (Figure 4.1).  M. haemolytica 1:A was the most frequently 
isolated organism from calves given 25 µg of plasmid DNA per nostril.  However, M. 
haemolytica 1:A was only isolated with a 17% frequency from experiment III control 
calves and a 8% frequency from calves given 50 µg of plasmid DNA per nostril.  Again 
M. haemolytica 1:A was not isolated from any calf given 100 µg of plasmid DNA per 
nostril.   
  Bacteria isolated from both summer and fall experiments on direct and 
enrichment media include Achromobacter, Pseudomonas, Micrococcus, 
Corynebacterium, Bacillus, Streptococcus, and more (Tables 4.1-4.5, Figure 4.1).  
Escherichia coli was isolated several times from both groups in experiment II, but was 
never isolated during experiment III.  Other Escherichia species were isolated during both 
experiments, but were isolated more frequently during experiment II (Figure 4.1).  An    90
   Experiment II   Experiment II   Experiment III   Experiment III   Experiment III    Experiment II   Experiment II   Experiment III   Experiment III   Experiment III
      controls   25 µg/nostril       controls    50 µg/nostril   100 µg/nostril       controls   25 µg/nostril       controls    50 µg/nostril   100 µg/nostril
Mannheimia 1:A Flavobacterium spp.
   haemolytica
2 9 % 6 3 % 1 7 % 8 %0 % 0 %0 %0 %4 %0 %
Achromobacter spp. Micrococcus spp.
17% 21% 17% 21% 21% 50% 42% 67% 63% 75%
Acinetobacter spp. Corynebacterium spp.
0% 4% 0% 0% 0% 38% 33% 83% 96% 92%
Pseudomonas spp. Baccilus spp.
0% 13% 0% 0% 4% 33% 17% 50% 50% 46%
Alcaligenes spp. Streptococcus spp.
0% 4% 0% 0% 0% 25% 8% 17% 17% 13%
Escherichia coli Staphylococcus spp.
17% 17% 0% 0% 0% 4% 8% 4% 4% 0%
Escherichia spp. Streptomyces
17% 25% 4% 0% 4% 4% 0% 8% 0% 0%
Coliform* Lactobaccilus spp.
0 %0 %1 3 % 0 %0 % 4 %8 %0 %0 %0 %
Gram-negative Peptococcus spp.
   coccus*
4% 4% 0% 0% 0% 4% 0% 0% 0% 0%
Citrobacter spp.
KEY:
DAY
4% 4% 0% 0% 0%    CALF 037 1 4 2 1 2 8
Chromobacter spp. 1 ISOLATIONS:
2 N E G A T I V E
3  POSITIVE
4
0% 4% 0% 0% 0% % FREQUENCY *Unable to identify  
Figure 4.1.  Frequency of bacterial isolations from nasal aspirates on direct and enrichment media  91
unidentifiable Gram-negative coccus was isolated once from an experiment II control calf 
(Table 4.1) and once from a calf given 25 µg of plasmid DNA per nostril (Table 4.2).  An 
unidentifiable coliform was isolated on direct media once from an experiment III control 
calf (Table 4.3) and twice on enrichment media from 2 different experiment III control 
calves. 
  Percent frequency of the nasal flora isolations were different between experiments 
II and III, but were consistent among the groups in each experiment (Figure 4.1).  
Micrococcus spp. were the most frequently isolated organisms in experiment II.  
Micrococcus spp. were isolated with a 50% frequency from experiment II control calves 
and a 42% frequency from calves given 25 µg of plasmid DNA per nostril.  In experiment 
III, Micrococcus spp. were isolated with an 67% frequency from experiment III control 
calves, a 63% frequency from calves given 50 µg of plasmid DNA per nostril and a 75% 
frequency from calves given 100 µg of plasmid DNA per nostril.  Corynebacterium spp. 
were isolated with a 38% frequency from experiment II control calves and a 33% 
frequency from calves given 25 µg of plasmid DNA per nostril.  In contrast, 
Corynebacterium spp. were the most frequently isolated organisms in experiment III.  
Corynebacterium spp. were isolated with an 83% frequency from experiment III control 
calves, a 96% frequency from calves given 50 µg of plasmid DNA per nostril and a 92% 
frequency from calves given 100 µg of plasmid DNA per nostril.  Bacillus spp., 
Streptococcus spp., and Achromobacter spp. were also frequently isolated from calves in 
both experiments. 
  There were no fluctuations in the average amounts of Gram-positive or Gram-
negative bacteria (CFU) isolated from either group in experiment II (Table 4.6, Figures   92
4.2 and 4.3).  Also, there were no fluctuations in the average amounts of Gram-positive 
bacteria (CFU) isolated from any group in experiment III (Table 4.7, Figure 4.4).  
However, there were drastic fluctuations in the average amounts of Gram-negative 
bacteria (CFU) isolated from all groups in experiment III (Table 4.7, Figure 4.5).   
Table 4.6.  Mean Gram-positive bacteria, Gram-negative bacteria and M.  haemolytica 
(CFU) per group isolated from experiment II calves on direct media. 
 
                      DAY       
GROUP     0  3  7  14  21  28 
E25  Gram (+)  3.9x10
5 1575 1.4x10
4 3x10
4 4.3x10
4 6.5x10
4 
 Gram  (-)  >9.8x10
5 4.8x10
4 2.6x10
5 3.9x10
4 2.2x10
4 9.3x10
4 
  Mannheimia        
    haemolytica  0 4.8x10
4 1.4x10
5 3.6x10
4 6750  7800 
              
Controls  Gram (+)  8.2x10
4 2.8x10
4 8038  4050 1.8x10
4 2900 
 Gram  (-)  1.5x10
4 3.1x10
4 5.3x10
4 1025 1.4x10
4 1775 
  Mannheimia        
    haemolytica  0 3.1x10
4 5.3x10
4 750  8750  0 
E25=calves given 25 µg of DNA per nostril 
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Figure 4.2.  Mean Gram-positive bacteria per group isolated from experiment II calves 
on direct media. 
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Figure 4.3.  Mean Gram-negative bacteria per group isolated from experiment II calves 
on direct media. 
 
 
 
 
Table 4.7.  Mean Gram-positive bacteria, Gram-negative bacteria and M. haemolytica 
(CFU) per group isolated from experiment III calves on direct media. 
 
                      DAY       
GROUP     0  3  7  14  21  28 
E50  Gram (+)  2.4x10
4 1.2x10
4 2x10
4 8.8x10
4 2.5x10
4 4.8x10
4 
 Gram  (-)  0  750  4875  1x10
4 0  0 
  Mannheimia        
    haemolytica  0 0 0  1x10
4 0  0 
          
E100  Gram (+)  3.3x10
4 1.1x10
4 2.8x10
4 1.3x10
5 1.4x10
5 3.8x10
5 
 Gram  (-)  5.3x10
4 988  1000  7500  0  0 
  Mannheimia        
    haemolytica  0 0 0 0 0 0 
              
Controls  Gram (+)  3.9x10
4 7.2x10
4 4.3x10
4 5550 6.5x10
4 1.3x10
5 
 Gram  (-)  0  2488  2.5x10
4 0  0  150 
  Mannheimia        
    haemolytica  0 1250  1.7x10
4 0  0  0 
E50=calves given 50 µg of DNA per nostril 
E100=calves given 100 µg of DNA per nostril 
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Figure 4.4.  Mean Gram-positive bacteria per group isolated from experiment III calves 
on direct media. 
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Figure 4.5.  Mean Gram-negative bacteria per group isolated from experiment III calves 
on direct media. 
 
On several days during experiment III no Gram-negative bacteria were isolated.  Mean 
Gram-negative bacteria colony counts for control calves dropped to 0 at day 14, but 
increased slightly by day 28 as seen in figure 4.5.  In contrast, mean Gram-negative 
bacteria colony counts for calves given 50 µg or 100 µg of plasmid DNA per nostril 
dropped to 0 at day 21, and did not increase by day 28 (Figure 4.5).     95
  In both experiments II and III M. haemolytica 1:A was more often isolated with 
Gram-positive bacteria than with Gram-negative bacteria (Table 4.8).  M. haemolytica 
1:A was isolated with Gram-positive bacteria 84% of the time, while it was isolated with 
Gram-negative bacteria only 34% of the time.  Corynebacterium spp. were isolated with 
M. haemolytica 1:A 11 times (29% frequency).  Also, Micrococcus spp. and Bacillus spp. 
were isolated with M. haemolytica 1:A 9 times (24% frequency) and 8 times (21% 
frequency) respectively.   
Table 4.8.  Bacteria isolated with M.  haemolytica 1:A on both direct and enrichment 
media. 
 
Bacteria Frequency
Frequency 
%  Rank 
None 5  13%  4 
Achromobacter spp.  5 13%  4 
Bacillus spp.  8 21%  3 
Corynebacterium 
spp.  11 29%  1 
Escherichia spp.  2 5%  6 
      Escherichia coli 4  11% 5 
Gram-negative 
coccus 2  5%  6 
Micrococcus spp.  9 24%  2 
Staphylococcus spp.  1 3%  7 
Streptococcus spp.  5 13%  4 
      
Gram-positive spp.  32  84%   
Gram-negative spp.  13  34%    
Note: M. haemolytica 1:A was isolated 38 times.   
 
Discussion  
  The major etiologic agent of bovine pneumonic pasteurellosis is Mannheimia 
haemolytica 1:A (Dalgleish, 1990, Frank, 1986), which is believed to be part of the 
normal bacterial flora in the URT of clinically healthy cattle; and can exist in the nasal 
cavity in very low numbers (Carter et al., 1991, Whiteley et al., 1992).  It is believed that   96
healthy cattle can carry undetectable levels of M. haemolytica 1:A for long periods of 
time (Frank, 1988).  M. haemolytica 1:A was not isolated from any calf in either 
experiment prior to challenge.  The organism is likely carried in one or more sites distinct 
from the nasal cavity, specifically the palatine tonsils (Frank et al., 1992).  While 
remaining in the tonsils, M. haemolytica 1:A is available for stress induced colonization 
of the nasal cavity.  In these experiments all calves were stressed, after challenge, by 
transportation in a crowded trailer, 100 miles for 3 hours.  Seven out of the 8 control 
calves for the 2 experiments yielded detectible levels of M. haemolytica 1:A in nasal 
aspirates throughout the weeks following challenge.  Stressed cattle have been shown to 
shed larger numbers of the bacterium (Frank et al., 1986).  Calves aerosolized with 25 µg 
of plasmid DNA per nostril did not gain any protection against M. haemolytica 1:A.  All 
4 of these calves yielded detectible levels of M. haemolytica 1:A in nasal aspirates.  
Furthermore, M. haemolytica 1:A was the most frequently isolated organism from calves 
given 25 µg of plasmid DNA per nostril.  As early as 1969 it was shown that M. 
haemolytica was capable of out numbering the rest of the nasal flora for several days at a 
time (Magwood et al., 1969).  M. haemolytica 1:A isolated from control calves and calves 
given 25 µg of plasmid DNA per nostril also fluctuated in frequency and numbers.  Two 
of the 4 calves given 50 µg of plasmid DNA per nostril yielded detectible levels of M. 
haemolytica 1:A in nasal aspirates following challenge.  However, M. haemolytica 1:A 
was not detected in any calf given 100 µg of plasmid DNA per nostril at any point during 
experiment III.  Calves aerosolized with 50 or 100 µg of plasmid DNA per nostril 
appeared to gain some or total protection to M. haemolytica 1:A, respectively.   97
  The nasal passage of cattle is home to a diverse collection of bacteria that make 
up the normal and transient flora.  These species of bacteria have been found to start 
colonizing the URT as early as the calf’s first day of life, and the total bacterial load 
increases with age, and under the influence of environmental temperature (Woldehiwet et 
al., 1990).  Studies have shown that the population of bacteria in the nasal passage of 
calves fluctuates heavily in types and numbers (Magwood et al., 1969, Woldehiwet et al., 
1990).  Sometimes one genus or species is more dominant than others for random periods 
of time.  Here, M. haemolytica 1:A was shown to dominate the nasal passages of  calves 
at several collection days during both experiments.  Also, fluctuations in the types and 
numbers of bacteria were observed in individual calves.  The percent frequency of nasal 
flora isolates were different between the summer and fall experiments, but were 
consistent among the groups in each experiment.  These results indicate that these 
organisms were always present at some level, but may have been increased or reduced 
due to environmental temperature.  Micrococcus spp. were the most frequently isolated 
organisms in experiment II control calves.  However, Micrococcus spp. were isolated less 
frequently than M. haemolytica 1:A from calves given 25 µg of plasmid DNA per nostril.  
It is believed that most Micrococcus spp. are heavily circulated in the air, and may not be 
able to colonize the nasal mucosa (Magwood et al., 1969).  Since they are regularly 
isolated from the nasal passage they may still be considered part of the normal flora.  
More frequent isolation of Micrococcus spp. during the summer experiments may have 
been a result of drier weather.  Corynebacterium spp. were isolated from all experiment II 
calves, but not as frequently as M. haemolytica 1:A and Micrococcus spp.  During the fall 
months of experiment III, Corynebacterium spp. were the most frequently isolated   98
organism from control calves, calves given 50 µg of plasmid DNA per nostril and calves 
given 100 µg of plasmid DNA per nostril.  M. haemolytica 1:A  and Micrococcus spp. 
were isolated less frequently.  Bacillus spp. were isolated from calves in both the summer 
and fall experiments, although more frequently during the fall experiment.  In both 
experiments Bacillus spp. were isolated in lower numbers that most other organisms.  
Escherichia coli was isolated several times from both groups in experiment II, but was 
never isolated during experiment III.  Isolation of Escherichia coli may actually be the 
result of fecal material in and around the nostrils. 
There appeared to be no significant change in the normal bacterial nasal flora.  
However, there were drastic fluctuations in the average amounts of Gram-negative 
bacteria isolated from all groups in experiment III.  Mean Gram-negative bacteria colony 
counts for calves given 50 µg or 100 µg of plasmid DNA per nostril dropped late during 
the experiment, after which no Gram-negative bacteria were isolated again.  Mean Gram-
negative bacteria colony counts for control calves also dropped late in the experiment, 
after which only small amounts of Gram-negative bacteria were detected.  It appeared 
that transfecting the nasal passages of cattle may have affected the Gram-negative nasal 
flora.  However, due to drastic fluctuations in the average amounts of Gram-negative 
bacteria isolated from all groups in experiment III, including the control calves, 
transfecting the nasal passages of cattle with a gene coding for cecropin B did not 
significantly alter the normal indigenous and transient nasal flora. 
Bacteria which make up the normal indigenous and transient nasal flora may 
enhance or inhibit growth of M. haemolytica.  Bacillus isolates were found to inhibit the 
growth of M. haemolytica in vitro (Corbeil et al., 1985).  In contrast, several Gram-  99
positive bacteria such as Micrococcus, Corynebacterium, and Staphylococcus were found 
to efficiently enhance the growth of M. haemolytica in vitro (Corbeil et al., 1985).  In this 
study M. haemolytica 1:A was more often isolated with the Gram-positive bacteria, 
specifically Corynebacterium spp. and Micrococcus spp., than with Gram-negative 
bacteria. However, Bacillus spp. were isolated with M. haemolytica 1:A, although in low 
numbers.  Also, it may be important to note that these three groups of bacteria were the 
most frequently isolated from all calves in both experiments.  Even though studies have 
shown that the normal and transient flora of the nasal passage can significantly affect the 
colonization of M. haemolytica 1:A (Corbeil et al., 1985), no conclusions could be made 
from these results.  
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SUMMARY AND CONCLUSIONS 
 
  The nasal passages of calves were aerosolized with different amounts of plasmid 
DNA containing a gene coding for cecropin B.  Results indicate that the cecropin B gene 
or cecropin B mRNA expression can be detected in DNA or RNA extracted from nasal 
swabs or nasal aspirates.  Furthermore, the cecropin B gene could be detected for at least 
4 weeks post transfection.  Detection of the cecropin B gene prior to calves being 
transfected and in untreated control calves could implicate the possible presence of a 
native bovine cecropin or cecropin-like gene and is a new finding.  Since the detection of 
cecropin B DNA in untreated calves could be due to a native bovine cecropin, it is 
unclear whether or not levels of cecropin B DNA detected in transfected calves at 4 
weeks is a persistence of the transferred gene.  Further research may be necessary to 
determine the longevity of transfection.   
Transfecting calves with 50 or 100 µg of plasmid DNA per nostril provided 
sufficient copies the cecropin B gene to transfect areas of the nasal passage.  Transfected 
areas of the nasal passage expressed cecropin B detectable at the mRNA and peptide 
level.  Results of these experiments indicate that an aerosol of 25 µg of plasmid DNA per 
nostril was not enough to consistently transfect the nasal passage of calves.  However, 
when compared to the control group cecropin B mRNA expression was significantly 
increased in calves given 50 µg or 100 µg of plasmid DNA per nostril at 3 and 7 days 
post transfection.  When ELISA was used to detect the peptide in nasal aspirates, a 
significant increase in mean amounts of cecropin B was observed at day 14 in the two  
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groups of calves given 50 µg or 100 µg of plasmid DNA per nostril.  No such increase 
was observed in the control calves.   
Results of this study also indicate that cecropin B is very effective in inhibiting 
the virulent challenge strain of Mannheimia haemolytica 1:A in vitro.  Growth of this 
isolate was inhibited at a concentration of 2 µg/ml.  While establishing susceptibility 
guidelines was not the goal of this study, these results may warrant further testing with 
larger numbers of isolates to accurately determine susceptibility breakpoints for M. 
haemolytica 1:A.  Although proteolytic enzymes in the bovine nasal mucosa may degrade 
the peptide and inhibit antibacterial activity, no inhibition was observed by incubating 
cecropin B in bovine nasal secretion.  Furthermore, cecropin B was able to completely 
inhibit M. haemolytica 1:A growth in BHI broth within 20 minutes of incubation at 37°C. 
M. haemolytica 1:A was not isolated from any calf in either experiment prior to 
challenge. After challenge, calves were stressed by transportation in a crowded trailer 100 
miles for 3 hours.  Seven out of the 8 control calves yielded detectible levels of M. 
haemolytica 1:A in nasal aspirates throughout the weeks following challenge.  Calves 
aerosolized with 25 µg of plasmid DNA per nostril did not gain any protection to M. 
haemolytica 1:A.  All 4 calves given 25 µg of plasmid DNA per nostril yielded detectible 
levels of M. haemolytica 1:A in nasal aspirates.  Calves aerosolized with 50 or 100 µg of 
plasmid DNA per nostril appeared to gain some or total protection to M. haemolytica 
1:A, respectively.  Two of the 4 calves given 50 µg of plasmid DNA per nostril yielded 
detectible levels of M. haemolytica 1:A in nasal aspirates following challenge.  However, 
M. haemolytica 1:A was not detected in any calf given 100 µg of plasmid DNA per 
nostril.    
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The percent frequency of nasal flora isolates were different between the summer 
(II) and fall (III) experiments, but were consistent between the groups in each 
experiment.  These results indicate that these organisms were always present at some 
level, but may have been increased or reduced due to environmental temperature or 
competitive inhibition. There appeared to be no significant change in the normal bacterial 
nasal flora.  However, there were drastic fluctuations in the average amounts of Gram-
negative bacteria isolated from all groups in the fall experiment.  Mean Gram-negative 
bacteria colony counts for calves given 50 µg or 100 µg of plasmid DNA per nostril 
dropped late during the experiment, after which no Gram-negative bacteria were isolated 
again.  Mean Gram-negative bacteria colony counts for control calves also dropped late 
in the experiment, after which only small amounts of Gram-negative bacteria were 
detected.  It would appear that transfecting the nasal passages of cattle may have affected 
the Gram-negative nasal flora.  However, due to drastic fluctuations in the average 
amounts of Gram-negative bacteria isolated from all groups in the fall experiment, 
including the control calves, transfecting the nasal passages of cattle with a gene coding 
for cecropin B was not likely responsible for altering the normal nasal flora.  While 
transfecting the nasal passage of calves with 50 or 100 µg of plasmid DNA per nostril did 
appear to inhibit colonization of M. haemolytica 1:A, it did not appear to alter the normal 
indigenous and transient flora.   
It is beneficial to find new strategies for the control of pneumonic pasteurellosis.  
The use of gene therapy will help to eliminate primary M. haemolytica 1:A infection in 
cattle destined for the feedlots.  The findings here indicate that antimicrobial peptides 
such as cecropin B are useful in inhibiting M. haemolytica 1:A colonization.  They also  
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indicate that the upper respiratory tract may be transfected with genes coding for these 
antimicrobial peptides.  Transfected calves expressing cecropin B in the nasal passage 
exhibited elevated resistance to M. haemolytica 1:A.  This work will add important facts 
to the database necessary to plan strategies for control of shipping fever.   104
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APPENDIX A: LETTER OF PERMISSION 
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APPENDIX B: A NOVEL STRATEGY OF CONTROLLING SHIPPING FEVER
∗ 
 
 
  Bovine pneumonic pasteurellosis or shipping fever continues to be the major 
cause of clinical disease and death in feedlot cattle and has been estimated to result in 
over a billion dollars in annual losses in the beef cattle industry.  Feeder calves from the 
southeastern United States normally break with the disease within 30 days after shipment.  
The bacteria Mannheimia haemolytica (formerly Pasteurella haemolytica) is the 
organism most commonly associated with the disease.  There have been numerous 
attempts to develop effective vaccines against this disease since the 1950s, but despite 
these efforts, a vaccine that provides complete and consistent protection from pneumonic 
pasteurellosis in cattle is not available.  Most veterinarians rely on antimicrobial agents to 
treat the disease.  Streptomycin, tetracyclines, β-lactin antibiotics, chloramphenicol, 
sulfonamides, and trimethoprim-sulfonamide combinations have all been used to treat 
pneumonic pasteurellosis.  Ironically studies have shown M. haemolytica to have an 
increasing pattern of resistance to all of these antimicrobial agents. 
  We believe that stressed cattle experience a multiplication of M.  haemolytica 
bacteria in the upper respiratory tract.  Stress usually comes in the form of transportation, 
but can include crowding, irregular feeding or watering, abrupt climate changes and 
exposure to viral agents or a combination of the above.  Multiplication of M.  
haemolytica in the upper respiratory tract, especially the nasal cavity, results in 
deposition of the bacteria in the lung.  This direct lung exposure results in both an 
immune and an inflammatory response that interferes with clearance of the bacteria from 
the lung and therefore causes pneumonia. 
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  In the past we have shown that an aerosol vaccination of the upper respiratory 
tract resulted in deminished bacterial colonization of M.  haemolytica in that area, as well 
as prevention of colonization in the lung.  Rapid clearance of M.  haemolytica was 
achieved by stimulating a specific class of secretory antibodies that act at the level of the 
mucosal surface of the nasal cavity.  The importance of rapid clearance from the nasal 
cavity is that there is no longer a source of the organism for continued inhalation into the 
lung. 
  The device used to aerosolize the vaccine into the nasal passage was a siphon feed 
gun from a sandblasting system.  The gun uses the flow of compressed air to create a 
siphon.  We modified the gun in order to secure a tube of inoculum to the intake stem.  
We also attached a 3-inch piece of rubber tubing to the nozzle of the gun as an extension 
to ensure the vaccine was delivered into the nasal passage.  A compressed nitrogen 
cylinder equipped with a regulator provided the 40-psi needed to aerosolize the vaccine. 
  Recently, this system was used to deliver a gene encoding an antibacterial protein 
called cecropin B.  Cecropins were discovered in 1980, when it was noticed that the 
Cecropia moth (Hyalophora cecropia) responds to bacterial infection with very effective 
antibacterial activity.  The pupae synthesize several different classes of antibacterial 
proteins, but the more potent of these are the cecropins.  Cecropins are small strongly 
basic proteins, which have a broad spectrum of bactericidal activity, but are unable to 
disrupt mammalian cells.   This clearly implicates their possible usefulness as novel 
antibiotics.   
The cecropin B gene was first incorporated into a DNA vector which also 
contained genes encoding for all the enzymes necessary to transfer the cecropin B gene   114
into the recipient’s DNA.  The plasmid was then complexed to a lipid based transfecting 
reagent designed to deliver DNA to the nucleus of mammalian cells.  The reagent 
complexes with DNA and arranges it in compact structures, to ease entry into the cell.  
This reagent also stabilizes the plasmid DNA inside the cell by protecting it from 
enzymes meant to destroy foreign DNA.  The delivery system for the aerosol was the 
modified siphon-feed gun previously described.  All personnel involved in the DNA 
delivery were protected by wearing disposable coveralls, disposable latex gloves and 
HEPA filtered respirators to prevent accidental exposure.  The disposable coveralls and 
latex gloves were properly disposed as biohazardous waste. 
Twenty 300-500 lbs. crossbred beef calves were brought to the LSU Veterinary 
Science Farm in Baton Rouge LA and kept on pasture.  Calves were randomly assigned 
to 5 groups with 4 calves in each group.  Three groups were designated the experimental 
groups, and the other two were designated the control groups.  The 5 groups remained 
isolated throughout the experiment.  Each of the  experimental calves were given 
incremented amounts of DNA suspended in 3 ml of sterile Phosphate buffered saline (pH 
7.2) per nostril, aerosolized with 40-psi of pressure.  Control calves were aerosolized 
first, without DNA, then allowed to return to the pasture. The experimental calves were 
aerosolized one at a time, with that calf being the only calf allowed in the chute at the 
time.  All 20 (experimental and control) calves were challenged intranasally with a 
virulent strain of M. haemolytica suspended in 3 ml of sterile  Phosphate buffered saline 
(pH 7.2) per nostril. Following the inoculation, all calves were trucked separately (by 
groups) 100 miles for 3 hours to stress them.  Nasal swabs were collected on days 0, 3, 7,   115
14, 21 and 28.  Samples were submitted for bacterial culture.  Day 0 samples were 
collected prior to any treatment. 
M. haemolytica was not isolated from any calf at day 0.  However, after challenge 
M. haemolytica was isolated from 7 of 8 control calves at some point during the 
experiment.  M. haemolytica was isolated from 4 of 8 control calves at day 3, and 5 of 8 
calves from days 7 thru 28.  M. haemolytica was isolated from all 4 calves given 25µg of 
DNA per nostril at day 3.  M. haemolytica was also isolated from all 4 of these calves on 
days 7, 14, 21 or 28.  M. haemolytica was isolated from only 1 of 4  calves given 50µg of 
DNA per nostril at day 3, and only 1 of 4 calves from days 7 thru 28.  M. haemolytica 
was not isolated from any of the 4 calves given 100µg of DNA per nostril at any point of 
the experiment. 
Table B.1.  Summary of Mannheimia haemolytica isolated 
GROUP  Day 0  Day 3  Day 7-28  TOTAL 
Controls  0 of 4  4 of 8  5 of 8  7 of 8 
        
E25  0 of 4  4 of 4  4 of 4  4 of 4 
       
E50  0 of 4  1 of 4  1 of 4  2 of 4 
       
E100  0 of 4  0 of 4  0 of 4  0 of 4 
E25, Calves given 25 ug/ml of DNA per nostril 
E50, Calves given 50 ug/ml of DNA per nostril 
E100, Calves given 100 ug/ml of DNA per nostril 
   
It is beneficial to find novel strategies for the control of pneumonic pasteurellosis.  
The findings indicate that novel antimicrobial proteins such as cecropin B may be useful 
in inhibiting M. haemolytica colonization.  They also indicate that the upper respiratory 
tract may be transfected with the genes coding for these novel antimicrobial proteins.  
Transfecting the nasal passage of calves with sufficient copies of the cecropin B gene was   116
shown to inhibit colonization of M. haemolytica.  Inoculating calves with 100µg of 
plasmid DNA per nostril completely inhibited M. haemolytica colonization.  Inoculating 
calves with 50µg of plasmid DNA per nostril provided some resistance to M. haemolytica 
when compared to control calves.  However, inoculating calves with 25µg of plasmid 
DNA per nostril provided little or no resistance to M. haemolytica when compared to 
control calves. This work will add important facts to the database necessary to plan 
strategies for control of shipping fever.  
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